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Mdm2 and MdmX as Regulators of Gene Expression 
Lynn Biderman 
Mdm2 and MdmX are RING domain proteins that bind to and inhibit p53 
trans activation functions. Moreover, Mdm2 interacts with p53 and targets it for 
degradation. However, Mdm2 and MdmX function beyond a simple inhibition of 
p53, and increasing evidence suggests functions in regulation of target gene 
specificity by p53 as well as influencing gene expression through other 
transcription factors. In this dissertation we present two studies into the 
regulation of p53 target genes by MdmX and Mdm2.  
 
We found that MdmX is required for the full activation of the Mdm2 gene 
following cellular stress, but not of other p53 targets, such as p21. The resulting 
deficiency in Mdm2 induction after MdmX ablation results in impaired negative 
feedback loop, leading to prolonged p53 half life following DNA damage. In vitro, 
MdmX does not stimulate p53 interaction with Mdm2 promoter DNA. MdmX 
does, however, inhibit the binding of p53 to DNA to a much lesser extent than 
Mdm2 does. Strikingly, MdmX is required for optimal p53 binding to the Mdm2 
promoter in vivo. Thus, we have described a new mechanism by which MdmX 
can suppress p53, which is through transcriptional activation of p53’s principal 
negative regulator, Mdm2. 
PCNA is a DNA sliding clamp that is required for DNA replication and 
coordinates multiple aspects of DNA biology. It is reported to be both a direct 
activation target of p53, as well as an indirect repression target. We have 
examined the roles of Mdm2 and MdmX in the regulation of the PCNA gene. 
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 This dissertation is divided into four chapters. Chapter one is an 
introduction to p53, Mdm2 and MdmX. Chapter two is a draft of a manuscript 
published in Molecular and Cellular Biology entitled “MdmX is required for p53 
interaction with and full induction of the Mdm2 promoter after cellular stress” 
(Biderman et al., 2012. Mol Cell Biol 32, 1214-1225). Chapter three is a 
manuscript in preparation, which studies the regulation of PCNA levels and cell 















Cancer is a disease of uncontrolled cell division. Mammalian cells have 
evolved systems that guard their integrity and prevent damaged cells from 
replicating, thus inhibiting the developments of tumors. Central to this protection 
is the tumor suppressor protein p53. p53 functions as a transcription factor that 
responds to cellular stress conditions and promotes cell cycle arrest, senescence 
or apoptosis. The importance of p53 in restraining tumorigenesis is evidenced by 
it being mutated in over 50% of human cancers, in almost all types (Olivier et al., 
2010).  
 
Discovery of p53 
p53 was discovered in the late 1970s as a protein that associates with 
oncogenic products of DNA tumor viruses (Lane and Crawford, 1979; Linzer and 
Levine, 1979). By early 1990s it became clear that p53 functions as a tumor 
suppressor. It was identified as the most commonly mutated gene in human 
cancers (Vogelstein, 1990), and familial mutations in the p53 gene were 
identified as the cause of Li-Fraumeni syndrome, an autosomal dominant severe 
cancer pre-disposition syndrome (Malkin et al., 1990; Srivastava et al., 1990). 
Mouse studies further confirmed that p53 indeed functions to suppress tumor 
formation. Mice with a homozygous deletion of p53 develop normally but 
succumb to multiple tumor types, primarily lymphomas and sarcomas, and most 
die within 9 months (Donehower et al., 1992). Restoration of p53 in tumors leads 
to senescence and clearance or apoptosis and tumor regression (depending on 
tumor type), although some resistant tumors may develop. These studies 
demonstrate that p53 loss is important for tumor maintenance (Martins et al., 
2006; Ventura et al., 2007; Xue et al., 2007). Hyperactive truncated p53-
expressing mice, on the other hand, were protected from tumor development. 
However, the mice did die earlier than their wild type littermates due to premature 
aging phenotype (Maier et al., 2004; Tyner et al., 2002). Mice with increased 
levels of normally regulated p53 experience tumor protection without the 
premature aging phenotype (Garcia-Cao et al., 2002). These data suggest that 
there has to be the right balance in p53 activity. Too little can predispose to 
tumor formation, while too much leads to decreased cellularity and early aging. 
We will discuss how the cells achieve this fine balance throughout this section. 
 
p53 structure 
p53 is a transcription factor that functions as a tetramer of four identical 
393 amino acid protein subunits (Fig. 1.1A, modified from Joerger and Fersht, 
2008). Since about 40% of the protein is disordered, there is no available 
structure of the full-length protein. p53 is a modular protein, consisting of the N-
terminal trans-activation domain (TAD), followed by the proline-rich region (PRR). 
The central DNA binding core domain (DBD) is responsible for interacting with 
p53 response elements (p53 REs) in a sequence-specific manner. An 
unstructured linker connects the core domain to the tetramerization domain 
(TET) that precedes the regulatory extreme C-terminus (CT), which is involved in 
non-specific DNA interaction through multiple basic amino acids (reviewed by 
Joerger and Fersht, 2008). 
The N-terminal TAD interacts with multiple proteins, including the 
transcriptional co-activators p300/CBP (Scolnick et al., 1997) and PRMT1 (An et 
al., 2004) and the basal transcription machinery components (Liu et al., 1993) 
TAFII40, TAFII60 (Thut et al., 1995), to induce transcription of target genes. The 
TAD is a largely unstructured region when free in solution, but assumes structure 
upon interaction with binding partners, such as Replication Protein A 
(Bochkareva et al., 2005) and p300 (Teufel et al., 2007). The PRR is poorly 
conserved in sequence among species (Toledo et al., 2007), and its role and 
structure remain poorly understood. 
The central core domain of p53 and the tetramerization domain are both 
well-folded in solution and their structures, both free (Canadillas et al., 2006) and 
in complex with DNA, have been solved by multiple groups (Cho et al., 1994; 
Kitayner et al., 2006). The core domain co-ordinates Zn2+, which stabilizes the 
loop-sheet-helix motif that interacts with DNA (Cho et al., 1994). Most tumor-
associated p53 mutations occur within the DBD domain (Olivier et al., 2010). The 
TET domain structure suggests a formation of a “dimer-of-dimers”, formed 
primarily through hydrophobic interactions (Lee et al., 1994).  
The quaternary structure of p53 is still unsolved. There are currently 
various solved electron microscopy (EM) structures of full-length p53, suggesting 
two distinct structural models. The first is a cryoEM structure of mouse p53 
stabilized with ATP. It shows a cube-like shape, in which each dimer is formed by 
interaction between the C and N termini of adjacent subunits, forming the N/C 
node. Two dimers then form a tetramer through interaction between the core 
domains of one dimer and the N/C node of the other dimer (Okorokov et al., 
2006). The second model describes the structure of p53 on DNA, which was first 
suggested in 2007 (Tidow et al., 2007) and further supported by a recent 
publication (Melero et al., 2011). This model suggests that p53 forms tetramers 
through interaction of the four TET domains, forming a cross-like shape when 
free in solution. In the presence of DNA, the DBDs close around the p53 RE. 
There seems to be a great structural variability in p53 tetramer binding modes on 
DNA, which decreases as the length of the DNA oligonucleotides is reduced 
(Melero et al., 2011).  
 
The p53 Response Element and its recognition by p53 
The p53 RE is comprised of two half sites separated by a 1-13 bp spacer 
region. Each half site is an inverted repeat of two pentameric quarter sites with 
the following consensus sequence: 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ (el-Deiry 
et al., 1992; Funk et al., 1992). A global analysis of p53 interaction (Wei et al., 
2006) and alignment of experimentally validated p53 REs (Riley et al., 2009) 
have led to refinement of the consensus motif, allowing for nucleotide insertions, 
and accounting for different numbers of half-sites. The tetrameric p53 binds the 
p53 RE, with each subunit recognizing one quarter site, inducing bending of the 
DNA (Nagaich et al., 1999). It was recently shown that upon interaction with p53 
REs there is a conformational change in the L1 loop of the DBD domain, 
supporting an induced-fit model for p53-DNA interaction (Petty et al., 2011), a 
behavior characteristic to other sequence-specific DNA binding proteins (Spolar 
and Record, 1994). 
 
Regulation of p53 
p53 sits at the hub of multiple signaling pathways, thereby converging 
their signals to affect various cellular outcomes. It was first noted that p53 
becomes post-translationally stabilized after UV irradiation (Maltzman and 
Czyzyk, 1984). Subsequently, it became clear that p53 responds to a variety of 
cellular stress conditions (Sullivan et al., 2012). So far, p53 has been shown to 
be stabilized in response to the different forms of DNA damage that are caused 
by ionizing radiation, ultraviolet light, cross-linking and alkylating agents, and 
reactive oxygen species. Additionally, p53 responds to other forms of cellular 
stress, such as oncogene activation, hypoxia, nucleotide deprivation (reviewed 
by Appella and Anderson, 2001), ribosomal stress (Zhang and Lu, 2009) and 
starvation (Jones et al., 2005). Stress signals are relayed to p53 primarily 
through post-translational modifications, which depend on the type and extent of 
stress (Saito et al., 2003). p53 can be phosphorylated, acetylated, ubiquitinated, 
SUMOylated, neddylated, methylated, glycosylated and even ADP-ribosylated 
(reviewed by Appella and Anderson, 2001; Bode and Dong, 2004; Kruse and Gu, 
2009). Some of these modifications will be discussed further in the next sections. 
There is great inter-dependence between p53 post-translational 
modifications. For example, p53 Ser37 and/or Ser33 phosphorylation following 
UV irradiation promotes further acetylation of p53 at Lys320 and Lys382 by p300 
and PCAF (Sakaguchi et al., 1998).  
p53 is modified primarily in two domains: the N-terminal TAD and the 
basic extreme C-terminus. Modifications of the p53 N-terminal domain serve a 
dual purpose: they promote stabilization of p53 through inhibition of its interaction 
with its main negative regulator Mdm2 (for example, Ser15 and Thr18 
phosphorylation was shown to reduce the p53:Mdm2 interaction (Sakaguchi et 
al., 2000; Shieh et al., 1997; Teufel et al., 2009)). Additionally, they enhance the 
trans-activation activity of p53 (for example through recruitment of p300/CBP 
(Avantaggiati et al., 1997; Gu et al., 1997)). Thus, phosphorylation can serve as 
a switch between p53 inhibition by Mdm2 and activation by p300/CBP. It has 
been shown that Thr18 phosphorylation exerts maximal switching effect when 
phosphorylated individually, but the strongest effect was observed upon 
phosphorylation of all serines and threonines in the TAD (Avantaggiati et al., 
1997; Lee et al., 2010).  
The p300 co-activator functions at two levels in p53-mediated trans-
activation: it acetylates histone proteins at the promoter, enabling access of the 
transcription machinery (reviewed by Brooks and Gu, 2011; Goodman and 
Smolik, 2000) and also acetylates p53 itself at multiple lysine residues at the 
extreme C-terminus. The effects of p53 acetylation are quite controversial. 
Although some authors report that p53 acetylation enhances its DNA binding 
activity (Gu and Roeder, 1997; Kobet et al., 2000), others show that p53 
becomes acetylated when already bound at the promoter site, and that this 
acetylation does not affect its DNA binding affinity (Dornan et al., 2003; Espinosa 
and Emerson, 2001). The latter authors believe that p53 acetylation functions in 
recruitment of cofactors. In addition to the six extreme C-terminal lysines, two 
lysines at the p53 core domain can also be acetylated: Lys120 by Tip60/hMOF 
(Sykes et al., 2006; Tang et al., 2006) and Lys164 by p300/CBP (Tang et al., 
2008). A non-acetylatable p53 mutant suggests that acetylation serves to de-
repress p53 by dissociating it from its negative regulators Mdm2 and MdmX on 
specific target promoters (Tang et al., 2008). 
 
Target gene selection 
p53 elicits specific responses based on the type and extent of stress 
signal in a tissue-dependent manner. Despite significant advancements in 
understanding how p53 selects its target genes, we still have not fully solved the 
question. Multiple mechanisms affect p53 target gene activation. (i) p53 protein 
level (ii) post-translational modifications (iii) differential protein binding (iv) target 
gene promoter architecture and co-factor binding (Vousden and Prives, 2009).  
p53 response elements widely vary in their sequence, the length of spacer 
between half-sites, and distance from transcription start site (Riley et al., 2008), 
all of which have been shown to affect p53 binding. The intrinsic specificity of p53 
DNA binding towards different RE sequences has been shown to affect target 
gene activation in a yeast system that controlled for chromatin position and co-
factor binding (Inga et al., 2002). p53 binding is optimal when the two half sites 
face the same direction on the double helix, with spacer of either 0 or 10 bp 
(Cook et al., 1995; Wang et al., 1995), and the distance of the RE from the TATA 
box and the sequence flanking the RE further influence p53 affinity towards DNA 
(Cook et al., 1995).  
As mentioned above, p53 post-translational modifications serve also to 
affect p53 target gene selection. For example, DNA damage-induced 
phosphorylation of p53 on Ser46 by Homeodomain-interacting protein kinase 2 
(HIPK2) is required for the induction of apoptosis via the transcriptional activation 
of p53AIP1 (Dauth et al., 2007; Oda et al., 2000; Smeenk et al., 2011; 
Wesierska-Gadek et al., 2007). Additionally, p53 phosphorylation of Ser15 and 
Ser392 serves as a switch between transcriptional repression and activation of 
the adenomatosis polyposis coli (APC) gene by p53 (Jaiswal and Narayan, 
2001). Acetylation of p53 also influences the outcome of p53 activation. p53 
acetylation by hMOF and TIP60 at Lys120 within the DNA binding domain is 
required for the activation of the pro-apoptotic genes Puma and Bax (Sykes et 
al., 2006; Tang et al., 2006). PCAF-mediated acetylation of Lys320, on the other 
hand, negatively regulates apoptosis induction by p53, as evidenced by the 
genes up-regulated by p53 in thymocytes from knock in mice containing non-
acetylatable mutant p53 (K317R in mice) compared to WT thymocytes that 
included the pro-apoptotic genes Puma, Noxa, Apaf1, Pidd, and Fas (Chao et al., 
2006).  
p53-binding partners can also affect promoter selectivity. Of the most well 
studied proteins in this respect are the ASPP family proteins. ASPP1 and its 
homologue ASPP2 interact with p53 to enhance the trans-activation of pro-
apoptotic p53 target genes and thus induce apoptosis (Beckerman and Prives, 
2010; Samuels-Lev et al., 2001). iASPP, on the other hand, interacts with p53 to 
inhibit the activation of pro-apoptotic targets (Bergamaschi et al., 2006). Another 
example of a p53 binding partner that affects p53 promoter selectivity is 
p18/Hamlet. p18/Hamlet is a p38 -regulated protein that, upon interaction with 
p53, promotes transcription of pro-apoptotic genes including Noxa and Puma, but 
not of other targets, such as p21 (Cuadrado et al., 2007; Lafarga et al., 2007). 
Activation of p53 target genes is greatly affected by target gene promoter 
architecture, including chromatin state and other transcriptional activator and co-
activator binding sites that act in concert with p53. One very clear example is the 
Mdm2 promoter polymorphism. A single nucleotide polymorphism (SNP309 T/G) 
has been described in human population (T/G in 40% and G/G in 12%). The G 
allele creates an additional SP1 binding site, increasing the affinity of SP1 to the 
Mdm2 promoter region, enhancing the transcription of Mdm2, hence leading to 
high Mdm2 levels in G/G cells (Bond et al., 2004). Furthermore, the G allele was 
shown to correlate with accelerated tumor formation in women (Bond et al., 
2006a; Bond et al., 2006b). Subsequent reports, however, showed conflicting 
results leading to meta analyses and comparisons between different studies to 
reconcile the different results, for example in endometrial cancer (Terry et al., 
2008), breast cancer (Economopoulos and Sergentanis, 2010), and leukemia 
and lymphoma (Post et al., 2010). 
It has recently been shown that the differential interaction of p53 with 
target genes in response to different stimuli cannot be recapitulated in p53 
binding to naked DNA, suggesting an important role of chromatin state in specific 
stress responses, rather than modulation of p53 affinity to the different REs 
(Millau et al., 2010). 
There is significant cross talk between the different mechanisms that 
influence p53 target gene selectivity. For example, phosphorylation of p53 on 
Ser46 leads to interaction with the prolyl-isomerase Pin1, which shifts p53 to a 
conformation unfavorable for iASPP binding, and thus promotes activation of 
apoptotic response (Mantovani et al., 2007). Additionally, the Mdm2 promoter 
architecture, containing two p53 REs in close proximity renders its activation 
independent of p53 C-terminal modification (Kaku et al., 2001). 
p53 is normally inhibited by its principal negative regulator, Mdm2, through 
multiple mechanisms. (1) Mdm2 binds to the p53 TA domain and prevents 
recruitment of transcriptional co-activators to target promoters (Oliner et al., 
1993; Teufel et al., 2007). (2) Mdm2 poly-ubiquitinates p53, targeting it for 
degradation via the ubiquitin-proteasome pathway (Haupt et al., 1997; Honda et 
al., 1997). (3) Mdm2 promotes mono-ubiquitination of p53, exposing a nuclear 
export signal, leading to its cytoplasmic translocation (Lohrum et al., 2001). (4) 
Mdm2 inhibits p53 mRNA translation indirectly, through promoting the 
degradation of the ribosomal protein L26 (Ofir-Rosenfeld et al., 2008), a protein 
that augments p53 translation (Takagi et al., 2005). MdmX is a structural 
homolog of Mdm2 that also functions as a negative regulator of p53-mediated 
transcription (Shvarts et al., 1996; Stad et al., 2000). MdmX, however, does not 
possess detectable E3 ligase activity (Stad et al., 2000). 
 Mdm2 is not the sole E3 ligase targeting p53. An effort of many 
laboratories has revealed a growing number of ubiquitin ligases that target p53 
for degradation (Jain and Barton, 2010). The elucidation of their biological 
functions, such as tissue or stimulus specificity, is just at the beginning. 
 
Mdm2 
Mdm2 was discovered as the second of three genes identified on a double 
minute chromosome present in transformed mouse fibroblasts (Fakharzadeh et 
al., 1991), hence its name Mouse Double Minute 2, or, Mdm2.  
The Mdm2 protein 
Human Mdm2 is a 491 amino acid multi-domain protein (Fig. 1.1B, 
modified from Wade et al., 2010). The Mdm2 N-terminal domain (amino acid 18-
101) is the primary site of interaction with p53 that inhibits its transcriptional 
activation function (Chen et al., 1993; Leng et al., 1995; Momand et al., 1992; 
Oliner et al., 1993). A linker contains a nuclear localization signal (NLS) and a 
nuclear export signal (NES) at positions 178 and 192 respectively. The central 
acidic region (amino acids 237-288) is important for ubiquitination of p53 (Kawai 
et al., 2003b; Meulmeester et al., 2003). It is directly followed by the zinc finger 
domain (amino acids 289-331), and both are sites of multiple protein-protein 
interactions (Manfredi, 2010). The C-terminus consists of a RING domain (amino 
acids 436-482), which possesses E3 ubiquitin ligase activity and is the site of 
interaction with MdmX (Sharp et al., 1999; Tanimura et al., 1999), and the 
regulatory extreme C-terminus (amino acids 485-491), which is required for 
optimal enzymatic activity of the RING domain (Poyurovsky et al., 2007; Uldrijan 
et al., 2007).  
 
The Mdm2-p53 interaction 
Mdm2 interacts with p53 through multiple regions. The first region of 
interaction identified is the Mdm2 N-terminal domain, which masks the TAD of 
p53, thus inhibiting its function (Chen et al., 1993; Leng et al., 1995; Momand et 
al., 1992; Oliner et al., 1993). A crystal structure of Mdm2 aa 1-109 and a p53 
TAD peptide revealed an interaction between an amphipathic helix formed by the 
TAD peptide and a hydrophobic cleft in the Mdm2 N-terminal domain (Kussie et 
al., 1996). A second region of interaction between Mdm2 and p53 resides in the 
Mdm2 central acidic domain that binds within the p53 DBD (amino acids 234–
286). This interaction is necessary for optimal ubiquitination of p53 (Ma et al., 
2006; Shimizu et al., 2002; Wallace et al., 2006; Yu et al., 2006). The acidic 
domain is also required for inducing a conformational change within p53, 
inhibiting its DNA binding ability (Cross et al., 2011). Recently, our laboratory has 
described an additional interaction between Mdm2 and p53, showing that the N-
terminus of Mdm2 interacts with the C-terminus of p53 (Poyurovsky et al., 2010), 
the major site of ubiquitin modification (Rodriguez et al., 2000). 
 
Regulation of the Mdm2-p53 interaction 
Since in unstressed conditions p53 is functionally inhibited and targeted 
for degradation by Mdm2, the activation of p53 in response to stress requires that 
the inhibition by Mdm2 be alleviated. Post-translational modifications of Mdm2 
and p53 are key to p53 activation in response to DNA damage, while protein-
protein interaction are mediating responses to other stresses such as ribosomal 
stress and oncogene activation and will be discussed in the section below. 
Activation of p53 following DNA damage 
 In response to DNA damage, cells activate a cascade of events that 
ensure cell cycle arrest, DNA damage repair and cell cycle re-entry, or activation 
of programmed cell death. The DNA damage response begins with the detection 
of DNA damage and continues by relaying the signal through transducers such 
as ATM and ATR to multiple effector proteins, including the kinases CHK1 and 
CHK2 (Bensimon et al., 2011; Chaturvedi et al., 1999; Ciccia and Elledge, 2010). 
ATM plays a crucial role in the activation of p53 following DNA damage (Kastan 
et al., 1992). 
Numerous studies have examined the effects of phosphorylation events 
on p53 activation. Following DNA damage, ATM or the DNA-dependent protein 
kinase (DNA-PK) phosphorylate p53 on Ser15 (Banin et al., 1998; Shieh et al., 
1997), while CHK2 phosphorylates p53 on Thr18 and Ser20, which reside within 
the region of interaction with Mdm2 (Chehab et al., 2000; Shieh et al., 2000). 
However, non-phosphorylatable mutants could still be activated, at least partially, 
following DNA damage (Ashcroft et al., 1999; Blattner et al., 1999; Dumaz and 
Meek, 1999), indicating other factors are involved. 
A more direct effect on p53 stabilization is attributed to Mdm2 
phosphorylation.  Mdm2 undergoes multiple phosphorylation events in a region 
adjacent to the RING domain following DNA damage (Khosravi et al., 1999), 
including on Tyr394 (Sionov et al., 2001), Ser395 (Maya et al., 2001), Ser407 
(Shinozaki et al., 2003), Ser386, Thr419, Ser425 and Ser429 (Cheng et al., 
2009). A non-phosphorylatable Mdm2 mutant is hyperactive towards p53, 
continuing to target it for degradation even following DNA damage, while 
phospho-mimic mutations are defective in p53 degradation. The defect in 
degradation of p53 is due to specific inhibition of p53 poly-ubiquitination, but not 
mono-ubiquitination (Cheng et al., 2009; Cheng et al., 2011).  
These results suggest that de-repression of p53 by inhibition of Mdm2 is 
central to p53 activation. Another line of evidence supporting this hypothesis 
emerged from analysis of the role of p53 acetylation on its activation. A non-
acetylatable p53 mutant cannot activate the transcription of most target genes 
due to the inability to dissociate from Mdm2 on target promoters following DNA 
damage (Tang et al., 2008). 
 
The Mdm2-p53 negative feedback loop 
The Mdm2 gene itself is a target of p53, thus forming a negative feedback 
loop upon p53 activation. Mdm2 is controlled by two promoters: the P1 promoter, 
which is constitutively active in most cells, though at low levels, and the p53 
responsive P2 promoter, located within Mdm2’s first intron, adjacent to its 
transcription start site (Barak et al., 1994). The Mdm2 P2 promoter contains two 
p53 binding sites, and is activated by p53 in response to various cellular stresses 
(Wu et al., 1993).  
The p53-Mdm2 negative feedback loop may lead to an oscillatory 
behavior. Following DNA damage p53 activates the transcription of Mdm2. Mdm2 
inhibits p53, and therefore Mdm2 production is also halted, leading to lower 
Mdm2 levels. When Mdm2 levels are low, p53 is stabilized etc. The peaks and 
timing of the oscillations depend on the type and strength of damage, and vary 
between cell types (Lev Bar-Or et al., 2000). Examination at a single cell level 
showed that ionizing radiation and the radiomimetic drug neocarzinostatin (NCS) 
induce an oscillatory behavior, while UV irradiation does not (Batchelor et al., 
2011). Furthermore, the oscillations exhibit some temporal variability, and a high 
variability in amplitude between individual cells (Geva-Zatorsky et al., 2006). 
Interestingly, in cells harboring the G/G Mdm2 SNP309 alleles, p53 induction is 
slower, as is the activation of the Mdm2 gene, leading to disruption of the 
oscillation (Hu et al., 2007). 
Wild-type p53-induced phosphatase 1 (Wip1) is another target of p53 that 
negatively feeds back to p53. Wip1 is a PP2C-like serine/threonine phosphatase 
that is induced following DNA damage (Fiscella et al., 1997). It counteracts p53 
by dephosphorylating its activators such as ATM and Chk2 among others (Lu et 
al., 2008), thus down regulating the stress response (Lu et al., 2007). 
Additionally, Wip1 dephosphorylates Mdm2 Ser395, an ATM phosphorylation 
site, leading to Mdm2 stabilization and inhibition of p53 (Lu et al., 2007). 
Accordingly, Wip1 is over-expressed in many tumor types (Le Guezennec and 
Bulavin, 2010). A theoretical model suggests that the activation of Wip1 following 
IR and subsequent ATM dephosphorylation is required for the oscillatory 
behavior of p53 and Mdm2 (Batchelor et al., 2011).   
Regulation of the Mdm2 P2 promoter 
The Mdm2 P2 promoter is regulated by multiple factors in addition to p53. 
These include the estrogen receptor (ER) in ER  positive cell lines (Phelps et al., 
2003), the thyroid hormone receptor in pituitary cell lines (Qi et al., 1999), the 
Ras-induced MAPK pathway (Ries et al., 2000), MYCN in neuroblastoma cells 
(Slack et al., 2005) and TGF  signaling (Araki et al., 2010), all in a p53-
independent manner. Furthermore, in MCF7 cells p53 binding to the Mdm2 
promoter does not require the chromatin remodeling protein Brg1, while the p21 
promoter does (Xu et al., 2007), suggesting a difference in the chromatin state 
between those two promoters, with the chromatin at the Mdm2 promoter being 
relatively open. This agrees with a report showing that in the murine embryonic 
fibroblast cell line 10-1 the Mdm2 locus is constitutively nucleosome free (Xiao et 
al., 1998). It was also shown, however, that expression of the Mdm2 promoter 
does require the histone acetyl transferase (HAT) activity of TRRAP, the catalytic 
subunit in multiple HAT complexes such as PCAF and STAGA (Ard et al., 2002). 
Therefore, more work is required for characterizing the requirement for HATs in 
the activation of the Mdm2 gene.  
 
Regulation of Mdm2 protein turnover 
Mdm2 protein turnover is regulated by the ubiquitin proteasome pathway, 
with the primary E3 ligase mediating ubiquitination of Mdm2 being Mdm2 itself 
(Fang et al., 2000; Honda and Yasuda, 2000). Following DNA damage, stress 
response kinases induce Mdm2 auto-degradation (Stommel and Wahl, 2004, 
2005). On the other hand, knock-in mice harboring an E3 ligase-dead mutant 
Mdm2 (C462A) demonstrated that the auto-ubiquitination activity of Mdm2 is not 
required for its degradation following DNA damage (Itahana et al., 2007), 
suggesting that other E3 ligases target Mdm2. 
Indeed, two such proteins have been reported to date. PCAF can 
ubiquitinate Mdm2 in vitro, and this activity in cells contributes to Mdm2 
degradation and p53 accumulation following DNA damage (Linares et al., 2007). 
Additionally, SCF -TRCP ubiquitinates Mdm2 that has been phosphorylated on 
multiple residues by Casein Kinase I following DNA damage (Inuzuka et al., 
2010a; Inuzuka et al., 2010b). Whether there is cross-regulation between the 
different E3 ligases targeting Mdm2 and their physiological roles requires deeper 
investigation. 
 
The oligomeric state of Mdm2 
Mdm2 proteins form multimeric structures in cells, though the 
stoichiometry of the complexes is not yet known. Cross-linking experiments in 
cells suggest that Mdm2 exists in large oligomers, and the RING domain is 
required for the formation of these high molecular weight complexes. DNA 
damage signaling inhibits the interaction between Mdm2 RING domains and 
disrupts the oligomeric structures (Cheng et al., 2009; Cheng et al., 2011). In 
vitro, Mdm2 oligomerization through RING-RING interaction is required for 
ubiquitin polymerization by Mdm2 (Poyurovsky et al., 2007). NMR structural data, 
however, showed that Mdm2 RING domains form dimers (Kostic et al., 2006). 
More work is required for resolving this discrepancy. The dimer structure may be 
the basic unit, which then forms higher complexity oligomers, but is the favorable 
stoichiometry formed by the RING domains undergoing the refolding protocol 
used for solving the NMR structure. 
 
Post-translational modifications of Mdm2 
 Mdm2 is regulated by post-translational modifications (Meek and Hupp, 
2010; Meek and Knippschild, 2003). As mentioned above, stress-induced 
modification of Mdm2 leads to its destabilization and therefore is crucial for p53 
accumulation and activation (Stommel and Wahl, 2005). Generally, 
phosphorylation of residues within the acidic domain promotes Mdm2-mediated 
degradation of p53, and Mdm2 becomes hypo-phosphorylated following DNA 
damage (Blattner et al., 2002), while phosphorylation of amino-acids between the 
Zn finger and RING domains inhibits p53 degradation and are induced following 
DNA damage (Hay and Meek, 2000). 
Additionally, Mdm2 is modified in response to growth and survival signals 
at residues near the nuclear localization and nuclear export signals, mediated by 
multiple kinases, including the p38 and ERK MAPK pathways in response to 
insulin-like growth factor -1 (IGF-1) and epidermal growth factor (EGF), leading to 
enhanced ubiquitination and degradation of p53 and decreased Mdm2 auto-
degradation (Feng et al., 2004; Mayo and Donner, 2001; Milne et al., 2004; Zhou 
et al., 2001).  
Phosphorylation of Mdm2 near the NES/NLS signals on Ser166, Ser186 
(Mayo and Donner, 2001; Zhou et al., 2001) and 188 (Milne et al., 2004) by Akt 
in response to mitogenic signals such as IGF1 or EGF promotes Mdm2 nuclear 
localization and enhanced p53 degradation (reviewed by Meek and Hupp, 2010). 
This effect of the Akt pathway was also shown to play a role in the accumulation 
of DNA damage in response to the stress hormone adrenaline (Hara et al., 
2011). Moreover, it may establish a positive feedback loop in the p53 pathway 
(Puszynski et al., 2008). p53 was shown to transcriptionally activate the tumor 
suppressor gene PTEN (Stambolic et al., 2001). PTEN is a negative regulator of 
the Akt pathway, thus leading to inhibition of p53 ubiquitination by Mdm2 and 
therefore further stabilization of p53. The scaffold protein -arrestin-1 functions 
downstream of the 2-adrenergic receptor. In response to stress hormone 
stimulation, -arrestin-1 induces Mdm2-mediated degradation of p53 both 
through the activation of PI3K/Akt and via directly stimulating Mdm2 interaction 
with p53 (Hara et al., 2011). 
 
Regulation of Mdm2 via protein-protein interactions 
 Mdm2 is also regulated by multiple binding proteins. While post-
translational modifications seem to be the primary regulators of Mdm2 following 
DNA damage, protein binding regulates Mdm2 following oncogenic and 
ribosomal stresses.  
Following oncogenic stress such as activation of Ras (Palmero et al., 
1998) or Myc (Zindy et al., 1998) an alternative reading frame (ARF) transcript 
from the INK4A locus is being activated. ARF interacts with Mdm2 and inhibits its 
activity towards p53 through sequestering Mdm2 in the nucleolus (Weber et al., 
1999) and also through inhibition of Mdm2’s E3 activity directly (Honda and 
Yasuda, 1999; Midgley et al., 2000).  
Ribosomal stress induces the release of multiple ribosomal proteins from 
the nucleolus, including RPL11 (Bhat et al., 2004), RPL5 (Dai and Lu, 2004), 
RPS7 (Zhu et al., 2009) and RPS3 (Yadavilli et al., 2009). These proteins interact 
primarily with the central domain of Mdm2 and inhibit ubiquitination of p53 
(Deisenroth and Zhang, 2010; Miliani de Marval and Zhang, 2011). The effects of 
ribosomal proteins on the p53 pathway is still under active investigation, and it 
appears that while many function through inhibiting ubiquitination of p53, some 
function through alternative ways. For example, RPL26 augments the translation 
of p53 mRNA (Takagi et al., 2005) and is itself a target of Mdm2-mediated 
ubiquitination, lowering p53 protein levels in unstressed cells (Ofir-Rosenfeld et 
al., 2008). 
The scaffold protein -arrestin-2 normally functions in G-protein-coupled 
receptor signaling at the plasma membrane (Buchanan and DuBois, 2006; 
Lefkowitz et al., 2006). Oligomeric forms of -arrestin-2, which do not localize to 
the plasma membrane, promote the cytoplasmic localization of Mdm2 leading to 
inhibition of p53 ubiquitination and degradation (Boularan et al., 2007; Wang et 
al., 2003).  
Mdm2 associates with the 19S cap of the 26S proteasome to form a p53-
Mdm2-proteasome ternary complex and promote the degradation of p53 (Kulikov 
et al., 2010). Both the N- and C- terminal domains of Mdm2 associate with the 
proteasome, and the association is regulated by phosphorylation of the Mdm2 
acidic domain. E3 activity of Mdm2, however, is dispensable for this activity 
(Kulikov et al., 2010). 
 
MdmX 
Human MdmX (also known as Mdm4 or HdmX) is a 490 amino acid RING 
domain p53 binding protein with high homology to Mdm2, especially at the N-
terminal p53-binding domain, and the C-terminal RING domain (Fig. 1.1C, 
modified from Wade et al., 2010). MdmX was identified in the mouse as a 
homologue of the Mdm2 protein that binds to the trans-activation domain of p53, 
and inhibits its activity (Shvarts et al., 1996) and the human orthologue was 
discovered shortly after (Shvarts et al., 1997). Despite the high homology to the 
Mdm2 RING domain, the MdmX RING domain does not degrade p53 in 
transfection experiments, and does not exhibit E3 ligase activity (Jackson and 
Berberich, 2000; Stad et al., 2000). However, MdmX does interact with Mdm2 
through their RING domains (Sharp et al., 1999; Tanimura et al., 1999), and this 
interaction affects both Mdm2 and p53 levels as will be discussed below. 
MdmX primarily localizes to the cytoplasm (Rallapalli et al., 1999), and its 
nuclear import depends on other proteins, as it lacks nuclear localization and 
export signals of its own. Co-expression of Mdm2 translocates MdmX into the 
nucleus (Gu et al., 2002a; Migliorini et al., 2002a) as well as co-expressed p53 
(Li et al., 2002). However, additional p53 and Mdm2-independent mechanisms 
exist that target MdmX to the nucleus following DNA damage (Li et al., 2002). 
 
Differences in the MdmX and Mdm2 interaction with p53  
Despite the high similarity between the Mdm2 and MdmX p53 binding 
domains, structural analysis of these regions from Mdm2 or MdmX bound to a 
p53 N-terminal TAD peptide shows that their p53 binding pockets are not 
identical. There are two amino acids partially blocking the hydrophobic pocket in 
MdmX (Popowicz et al., 2008; Popowicz et al., 2007). This finding helps explain 
why the small molecule inhibitor of the Mdm2:p53 interaction Nutlin-3 is relatively 
ineffective at disrupting the MdmX:p53 interaction (Joseph et al., 2010; Popowicz 
et al., 2007; Vassilev et al., 2004). Another difference between the way Mdm2 
and MdmX interact with p53 is demonstrated by the findings that while Mdm2 
strongly inhibits p53:DNA interactions (Cross et al., 2011; Poyurovsky et al., 
2010; Zauberman et al., 1993), MdmX does so at a much lesser extent (Cross et 
al., 2011). A recent study demonstrated another difference between the effects of 
Mdm2 and MdmX binding to p53 on p53 stability. MdmX was shown to protect 
p53 from ubiquitin-independent proteasomal degradation following DNA damage 
by affecting its conformation, while Mdm2 cannot perform this function (Di Conza 
et al., 2012).  
 Mice harboring a homozygous deletion of Mdm2 or MdmX 
demonstrate that Mdm2 and MdmX play unique non-overlapping functions in p53 
inhibition. Mdm2 knockout mice die early in utero, before 5.5 dpc. Co-deletion of 
p53 rescues the embryonic lethality, suggesting the embryos fail to develop due 
to unrestricted p53 activity (Jones et al., 1995; Montes de Oca Luna et al., 1995). 
MdmX deletion is also embryonic lethal, though at a later stage (10.5 dpc), and is 
rescued by co-deletion of p53 (Migliorini et al., 2002b; Parant et al., 2001). At 
high levels Mdm2 can compensate for the lack of MdmX, as MdmX null mice that 
over-express Mdm2 are viable (Steinman et al., 2005). These mice, however, are 
tumor prone and they develop tumors at an accelerated rate compared to mice 
that over-express Mdm2 in the presence of MdmX, suggesting tumor 
suppressive roles for MdmX.  
 
The Mdm2:MdmX complex 
As mentioned above, MdmX interacts with Mdm2 through their RING 
finger domains (Sharp et al., 1999; Tanimura et al., 1999) forming a complex. 
The effect on p53 stability depends on the ratio of Mdm2 to MdmX (Lenos and 
Jochemsen, 2011). Over-expression of MdmX was shown to stabilize Mdm2 and 
p53, and the MdmX RING domain is both necessary and sufficient for this activity 
(Stad et al., 2000). At very high levels, MdmX competes Mdm2 off p53, thus 
stabilizing p53 (Gu et al., 2002a), although the bound MdmX masks the TA 
domain, rendering p53 transcriptionally inactive. At a 1:1 ratio, on the other hand, 
MdmX inhibits Mdm2-mediated auto-ubiquitination, prolonging Mdm2’s half-life 
and facilitating Mdm2-mediated ubiquitination of p53 (Gu et al., 2002a; Kawai et 
al., 2007; Linke et al., 2008). 
The relative levels of Mdm2, MdmX and p53 are critical for their 
function. For example, Mdm2 or MdmX heterozygous mice are viable, but the 
double heterozygotes die in utero and are rescued by deletion of a single p53 
allele (Terzian et al., 2007). Furthermore, alterations in the amount of Mdm2 
protein expressed in mice result in a shift in p53 response, with high Mdm2 being 
permissive to tumorigenesis (Jones et al., 1998), normal levels supporting tissue 
homeostasis, while further reductions in Mdm2 levels lead to tumor suppression, 
tissue-specific apoptosis and eventually embryonic lethality due to unleashed 
p53 activity (Mendrysa et al., 2006; Poyurovsky and Prives, 2006). 
Formation of the Mdm2:MdmX complex is essential for embryonic 
development. Both an MdmX knock-in mouse harboring a mutation in its RING 
domain (C462A) rendering it unable to interact with Mdm2 (Huang et al., 2011) 
and a mouse with a truncated MdmX lacking the RING domain (Pant et al., 2011) 
die in utero due to enhanced p53 activity. Conditional deletion of MdmX RING 
domain in adult mice, however, did not cause any detectable phenotype, 
suggesting a primary role for the complex during development (Pant et al., 2011). 
 
Post-translational modifications of MdmX 
The abundance of the MdmX protein is regulated mainly post-
transcriptionally. Following DNA damage MdmX translocates to the nucleus in an 
Mdm2- and p53-dependent manner (Li et al., 2002), where Mdm2 targets it for 
degradation via the ubiquitin proteasome pathway (de Graaf et al., 2003; Kawai 
et al., 2003a; Pan and Chen, 2003). With MdmX playing a role in shifting the 
substrate specificity of Mdm2 in favor of p53 ubiquitination rather than Mdm2 or 
MdmX ubiquitination in unstressed cells, it came as no surprise that MdmX is 
heavily post-translationally modified, and these modifications play a role in 
shifting Mdm2 targets selection, destabilizing Mdm2 and MdmX and increasing 
p53 stability after DNA damage.  
Following certain types of damage, such as gamma irradiation and the 
radiomimetic drug neocarzinostatin (NCS), MdmX becomes phosphorylated on 
Ser342, Ser367 and Ser403 in an ATM/Chk2-dependent manner (Chen et al., 
2005a; Okamoto et al., 2005; Pereg et al., 2005). These phosphorylation events 
promote nuclear import of MdmX in a 14-3-3 dependent way (LeBron et al., 
2006), and promote Mdm2-mediated ubiquitination and degradation of MdmX, 
thus contributing to p53 stabilization (Okamoto et al., 2005). Whether MdmX 
plays a role in the nucleus prior to being degraded is not established yet, and we 
provide a possible function of nuclear MdmX in this work. The importance of 
phosphorylation of these serine residues for tumor suppression is seen in the 
MdmXS3A knock in mouse, in which the three serines have been mutated to 
alanines in an E -myc transgenic mouse background. MdmXS3A was resistant to 
DNA damage-induced degradation, leading to impaired p53 activity and 
increased radioresistance. Moreover, MdmXS3A accelerated lymphomagenesis in 
the knock in mice (Wang et al., 2009). 
DNA damage also induces phosphorylation of tyrosine residues on MdmX 
(Tyr55 and Tyr99) by c-Abl. Tyr99 is located within the p53 binding region, and 
its phosphorylation inhibits MdmX:p53 interaction, contributing to p53 activity 
(Zuckerman et al., 2009). 
In unstressed cells, MdmX is phosphorylated by CK1  on Ser298, 
enhancing the MdmX:p53 interaction (Chen et al., 2005b), and by CDK2/Cdc1p34 
on Ser96, enabling nuclear export of Mdm2 (Elias et al., 2005).  
 
Regulation of MdmX transcription 
Regulation of the MdmX promoter is much less explored than that of 
Mdm2, but similarities are already revealed. Like the Mdm2 gene, MdmX is also 
regulated by mitogenic signaling. The IGF-1 and ERK pathways were shown to 
up-regulate MdmX mRNA levels. Moreover, MdmX protein abundance correlates 
with active ERK signaling in colon tumors (Gilkes et al., 2008).  
Until recently, it was assumed that MdmX is not a transcriptional target of 
p53. This has now been challenged, with an MdmX P2 promoter within its first 
intron being discovered. A global analysis of p53 binding revealed a p53 RE in 
the MdmX gene locus (Wei et al., 2006). Following activation with Nutlin-3, p53 
activates transcription of MdmX mRNA in testicular germ cell tumors, forming a 
negative feedback loop (Li et al., 2010). The MdmX transcript controlled by the 
MdmX P2 promoter was then further characterized, revealing a novel mRNA 
species termed MdmX-L, in which 18 novel amino-acids are added at the N-
terminus. This transcript is more efficiently translated, and contributes to recovery 
from p53 activation following stress (Phillips et al., 2010).  
 
Tumor suppressive functions of MdmX 
MdmX promotes bipolar mitoses thus promoting genome integrity in a 
p53-independent manner (Matijasevic et al., 2008a; Matijasevic et al., 2008b). 
p53;MdmX null mice develop tumors earlier than p53 null mice, suggesting a 
tumor suppressive role of MdmX in cells lacking p53. Accordingly, MEFs lacking 
both MdmX and p53 exhibit accelerated proliferation and higher spontaneous 
transformation than cells lacking p53 alone. While p53 null MEFs become 
polyploid with increased passage number, MdmX co-deletion leads to reduced 
centrosomes clustering and multi-polar spindles, resulting in chromosome loss 
and lower ploidy (Matijasevic et al., 2008a; Matijasevic et al., 2008b). These 
results indicate a role for MdmX in maintaining genomic integrity. This function is 
specific to MdmX, as Mdm2 co-deletion does not affect the growth of p53 null 
MEFs (Jones et al., 1996).  
A tumor suppressive role for MdmX at the mitochondria has also been 
described. Cytoplasmic MdmX promotes p53-mediated apoptosis through 
localizing to the mitochondria and enhancing the mitochondrial localization of p53 
that was phosphorylated on Ser46. Thus, MdmX plays a role in inducing the p53-
mediated intrinsic apoptosis pathway in response to DNA damage (Mancini et al., 
2009).  
 
MdmX and Mdm2 as regulators of gene expression 
 There is mounting evidence that Mdm2 and MdmX affect most stages of 
gene expression. It seems now that Mdm2 and MdmX are not just blanket 
inhibitors of all p53-mediated transcription, but rather affect target gene 
selectivity by p53 in a cell-specific manner. They also affect the activity of other 
transcription factors such as E2F1 and Smad4 in a p53-independent manner, 
and Mdm2 itself was shown to affect chromatin state by ubiquitinating histone 
H2B. Furthermore, the Mdm proteins affect mRNA stability and translatability of 
specific transcripts. The next section will discuss our current knowledge of how 
Mdm2 and MdmX are involved in regulating gene expression. 
Regulation of target gene activation by p53 
 It was initially assumed that Mdm2 and MdmX are nondiscriminatory 
inhibitors of p53 transactivation functions. Multiple lines of evidence now suggest 
that Mdm2 and MdmX affect target gene selectivity by p53 in a cell and tissue 
specific manner. It has only recently become possible to study these functions of 
Mdm2 and MdmX in mice, thanks to conditional mouse models in which p53 is 
reactivated in adult tissues of mice lacking Mdm2 and/or MdmX as well as p53 
expression. 
 A hint into the differential effects of MdmX and Mdm2 on p53-mediated 
transcription is given by the phenotypes of the null mice. Mdm2 null mice die at 
5.5 dpc (Jones et al., 1995; Montes de Oca Luna et al., 1995). Bax deletion, 
although not suppressing the lethality of Mdm2 null mice, delays the death of the 
embryo, and the death is due to cell cycle arrest rather than apoptosis (Chavez-
Reyes et al., 2003). MdmX null mice die later in development, at 7.5-12 dpc due 
to proliferative arrest (Migliorini et al., 2002b; Parant et al., 2001). Deletion of the 
cell cycle arrest gene p21 partially rescues the phenotype (Chavez-Reyes et al., 
2003; Steinman et al., 2004). These results suggest that p53 activity in the 
absence of MdmX or Mdm2 is qualitatively different, activating specific outcomes. 
However, whether the activation of cell cycle arrest leading to death in the 
embryos lacking both Mdm2 and Bax resulted in from a timing delay in activation 
of p53, or due to another reason is not clear. To be more specific, it may be that 
activation of p53 at 7.5 dpc preferentially promotes cell cycle arrest, while 
activation of p53 earlier in development will result in death by apoptosis. 
 A more careful examination of the effects of Mdm2 and MdmX loss on p53 
activity was carried out in MEFs into which a temperature-sensitive p53  
(p53A135V) was engineered and showed that the phenotypes discussed above are 
not due to the timing of p53 activation, but rather due to specific effects of Mdm2 
and MdmX loss. p53A135V was introduced into MEFs that were isolated from mice 
lacking p53 and Mdm2 (TS 2), p53 and MdmX (TS X), or p53 alone (TS). At the 
permissive temperature (32ºC) p53 levels differed between the cell lines, with 
levels highest in TS 2, medium in TS and lowest in TS X. The low p53 levels in 
TS X were due to Mdm2-mediated degradation, as cells engineered from the 
triple knockouts (TS 2 X) did not exhibit low p53 levels. p53 reactivation in 
Mdm2 null MEFs resulted in apoptotic cell death, but not in MdmX nulls. TS 2 X 
behaved likeTS 2, while TS X cells exhibited primarily G1 arrest following p53 
reactivation despite of the low p53 levels. An examination of p53 target gene 
mRNAs revealed that in the TS X cells p53 activated Mdm2 and the cell cycle 
arrest gene p21, but not cyclin G, Bax, Perp, and Noxa. TS 2, on the other hand, 
activated the pro-apoptotic genes Perp and Noxa but not Cyclin G and Bax, while 
p21 was only slightly elevated. Thus, Mdm2 and MdmX determine the outcome 
of p53 activation through affecting target gene selectivity by p53 (Barboza et al., 
2008). A possible mechanistic explanation is that rather than directly influencing 
target gene activation, Mdm2 and MdmX simply affect p53 levels, and these, in 
turn, affect the outcome – cell cycle arrest when p53 levels are low vs. apoptosis 
when p53 levels are high. 
 A global look on alterations in gene expression following MdmX and 
Mdm2 knockdown in MCF7 breast cancer cells containing WT p53 has been 
taken (Heminger et al., 2009). In this system, knockdown of either Mdm2 or 
MdmX led to p21 induction and cell cycle arrest at the G1 phase, but no 
increased cell death. Apoptosis was increased in siMdmX and siMdm2 cells in 
response to DNA damage with doxorubicin or cisplatin. The authors focused on 
genes that were commonly affected by siMdm2 and siMdmX, identifying 394 
genes, out of which 222 were up-regulated in response to the knockdown. The 
list of genes was enriched for cell cycle arrest-promoting p53 target genes, 
including p21, BTG2 and ACTA2. The remainder 172 genes were down-
regulated in the knockdown cells, and were enriched for E2F1 target genes, 
consistent with repression of E2F1 activity by the elevated p21. It would be 
interesting to analyze the microarray data for genes differentially affected in 
siMdm2 vs. siMdmX-treated cells. 
 Conversely, another study examined the effect of excess Mdm2 on p53-
mediated target gene activation (Ohkubo et al., 2006). The authors engineered 
extra Mdm2 to be expressed in H1299 lung cancer cells that contain tetracycline-
regulatable p53 (Chen et al., 1996). The excess Mdm2 did not affect p53 levels 
nor localization, but did impact target gene activation. Following p53 induction by 
removal of tetracycline the following tested p53 target genes were activated in 
control cells: p21, Bax, 14-3-3  and PIG-3. In the cells expressing excess Mdm2, 
however, 14-3-3  and PIG-3 mRNA levels were markedly reduced, while p21 
and Bax expression was unaffected. The outcome of p53 activation was thus 
altered by the excess Mdm2, from primarily G1 arrest with little G2 arrest in 
control cells to significantly increase G2 arrest in cells expressing excess Mdm2. 
 A recently published mouse model of inducible p53 in the background of 
either MdmX or Mdm2 knockout enables analysis of transcriptional responses to 
p53 activation in the absence of Mdm2 or MdmX in vivo. 4-hydroxy-tamoxifen (4-
OHT)-dependent p53 (p53ERTAM) knock in mice that express p53 from its 
endogenous locus in response to 4-OHT were generated in MdmX WT, MdmX-/- 
or Mdm2-/- background. Systemic reactivation of p53 in the adult MdmX-/- mice 
leads to activation of p53 target genes in a tissue specific manner. p21 was 
induced in all tested tissues except the small intestine, while the pro-apoptotic 
target Puma induction was restricted to the bone marrow, spleen thymus and 
intestine – the classic radiosensitive tissues. Accordingly, the tissues expressing 
Puma exhibited increasing apoptosis. However, in spite of these responses to 
p53 activation, the mice were viable and recovered well from 7 day sustained 
p53 activation. The intestines maintained function despite of ongoing apoptosis, 
probably due to the continued proliferation resulting in from lack of p21 activation 
in this tissue (Garcia et al., 2011). This response is surprising in the light of the 
previously published results of p53 activation in Mdm2-/- background, where mice 
could not sustain a transient p53 restoration and suffered severe loss of intestinal 
barrier function leading to death within 6 days (Ringshausen et al., 2006). In this 
mouse model of p53 reactivation, restored p53 levels in MEFs were higher in the 
absence of MdmX than in WT cells (Garcia et al., 2011), in contrast to the model 
discussed above from Barboza and co-authors, where levels of TS p53 were 
lower in the absence of MdmX than in its presence (Barboza et al., 2008). Thus, 
inherent differences between the experimental systems may influence the 
outcome of p53 activation, from which we may learn about the factors influencing 
the response to p53 activation in different contexts. 
 
Indirect regulation of p53 activity by Mdm2 
 Another way through which Mdm2 affects gene expression by p53 is 
through regulating the proteins that post-translationally modify p53. As mentioned 
above, multiple post-translational modifications of p53 influence its target gene 
activation. Some of these modifiers are themselves targets of ubiquitination and 
degradation by Mdm2. These include the histone acetyl transferases PCAF (Jin 
et al., 2004) and Tip60 (Legube et al., 2002). Moreover, Mdm2 inhibits p300 (Ito 
et al., 2001; Kobet et al., 2000) and PCAF (Jin et al., 2002) -mediated acetylation 
of p53. While Kobet and co-authors report that Mdm2 binds to p300 and to p53 
via separate domains forming a ternary complex (Kobet et al., 2000), Matt and 
co-authors show that there is no specific interaction between Mdm2 and p300 
(Matt et al., 2004). Teufel and co-authors (2007) reconcile this dispute by 
mapping four regions on p300 that interact with the transcriptional activation 
domains of p53 TAD1 and TAD2. The interaction was measured to be of 
comparable affinity to that of Mdm2 to TAD1, and using competition assays they 
show mutually exclusive binding of p300 or Mdm2 to p53 TAD1/2 peptide. They 
hypothesize that p300 monomers may wrap around the p53 tetramer, binding 
through the four interaction domains, and other high affinity p53 interacting 
proteins such as Mdm2 or MdmX can displace p300 off of some of the p53 
monomers, leading to the formation of hybrid complexes without direct interaction 
between the Mdm2 protein and p300 (Teufel et al., 2007). Structural analysis 
supports a model of ternary complex formation with Mdm2 interacting with TAD1 
and p300 interacting with TAD2 (Ferreon et al., 2009). 
 HATs are not the only p53 modifying enzymes regulated by Mdm2. The 
kinase HIPK2, which phosphorylates p53 on Ser46 thus promoting apoptosis, is 
also a target of Mdm2. Over expression of Mdm2 mutant that cannot bind to and 
degrade p53 but can still degrade HIPK2 results in lower p53 Ser46 
phosphorylation and compromised cell death in response to lethal dose of 
doxorubicin (Rinaldo et al., 2007). HIPK2 promotes apoptosis also through a 
p53-independent mechanism, through the inhibition of the transcriptional co-
repressor CtBP (Zhang et al., 2003). Therefore, by down regulating HIPK2 Mdm2 
may affect transcription by p53 as well as by CtBP. 
 Mdm2 can also influence p53 transcriptional activity through targeting its 
cofactors Junction-Mediating and Regulatory protein (JMY) and heterogeneous 
nuclear ribonucleoprotein K (hnRNP K) for degradation. JMY is a cofactor of 
p300 that augments p53 mediated transcriptional activation and apoptosis 
(Shikama et al., 1999). More recently, cytoplasmic JMY has been implicated in 
the nucleation of actin filaments promoting cell motility (Zuchero et al., 2009). 
Mdm2 interacts with JMY and targets it for proteasomal degradation, reducing 
the level of nuclear JMY. Following DNA damage, the Mdm2:JMY interaction is 
reduced and JMY accumulates in cells. This accumulation is enhanced in cells 
treated with the Mdm2:p53 inhibitor Nutlin-3. Accumulated JMY then functions in 
augmenting the apoptotic response, as demonstrated by down-regulation of JMY 
leading to decrease in apoptosis and increased G1 arrest in UV-treated cells 
(Coutts et al., 2007). 
 hnRNP K is a poly-C binding protein that can interact with both DNA and 
RNA via its hnRNP K homology (KH) domain. hnRNP K is involved in 
transcription control through multiple ways, regulating the expression of c-Myc, 
SRC and BRCA1 among others (reviewed by Choi et al., 2009). hnRNP K 
accumulates in cells following DNA damages, and is recruited to p53 target 
promoters in a p53-dependent manner. It is required for efficient recruitment of 
p53 to its target promoters and for induction of p53 target genes. siRNA to 
hnRNP K severely impairs cell cycle arrest following DNA damage. hnRNP K is a 
target of Mdm2-mediated ubiquitination, and its stabilization following DNA 
damage requires inhibition of its ubiquitination (Moumen et al., 2005). How 
hnRNP K functions in p53 recruitment and target gene activation is still unclear. It 
also remains to be determined whether hnRNP K is required for induction of all 
p53 targets, or a specific subset. 
 
Regulation of transcription factors other than p53 
 In addition to affecting transcription through directly or indirectly 
modulating p53 mediated target gene activation, Mdm2 and MdmX affect gene 
expression mediated by other transcriptional activators that control cell cycle 
progression. 
 Transforming growth factor  (TGF ) is a family of five cytokines that play 
roles in cell proliferation, migration, differentiation and apoptosis. All TGF s 
activate the TGF  Ser/Thr kinase receptors, which signal through 
phosphorylation of Receptor Smad proteins (RSmads). Phosphorylated RSmads 
translocate to the nucleus, bind Smad4 and other cofactors and function as 
transcription factors, leading to both tumor promoting as well as suppressing 
outcomes, depending on the cellular context. Among the genes regulated by 
Smad proteins are the CDK inhibitors p21 and p27 (Massague, 2008).  
 Mdm2 was initially shown to inhibit TGF  signaling independent of p53 in 
a screen for TGF  suppressor cDNAs (Sun et al., 1998). Further investigation 
revealed that in an over-expression system, Mdm2 suppresses the activity of 
Smads1, 2, 3, and 4. Moreover, both Mdm2 and MdmX exhibit inhibitory 
functions towards Smad4 through affecting its sub-cellular localization, leading to 
its exclusion from the nucleus. Curiously, Neither Mdm2 nor MdmX form a 
complex with Smad4, leaving the mechanism for cytoplasmic sequestration upon 
co-expression unsolved (Yam et al., 1999). A second study showed that MdmX 
but not Mdm2 inhibit co-expressed Smad3 and Smad4 transcriptional activity 
(Kadakia et al., 2002) (Mdm2 still exhibited some inhibitory effect on endogenous 
Smads). The authors did not see any effect of Mdm2 or MdmX on Smad 
localization. A possible explanation for the discrepancy is that Yam and co-
authors performed their analyses in HeLa cells while Kadakia and co-authors 
used H1299 cells. Over-expression of p300, a cofactor for Smad transcriptional 
activation reverses the Smad inhibition exerted by over-expressed MdmX 
(Kadakia et al., 2002). 
 Mdm2 regulates -arrestin-mediated signaling from a variety of G-protein-
coupled receptors (GPCRs), initially discovered in 2-adrenergic receptor 
signaling (Lefkowitz et al., 2006). Following activation of the 2-adrenergic 
receptor, -arrestin-2 recruits Mdm2 to the activated receptor. Mdm2 poly-
ubiquitinates the scaffold protein -arrestin-2, leading to receptor internalization. 
Additionally, Mdm2 poly-ubiquitinates the receptor itself, promoting its 
degradation (Shenoy et al., 2001). -arrestin-2, however, is not degraded 
following its ubiquitination, and can function in signal transduction. Moreover, the 
E3 activity of Mdm2 was shown to be required for -arrestin-2 cytoplasmic 
localization and signal transduction function (Yin et al., 2011). Some receptor 
tyrosine kinases are also regulated by Mdm2 in a similar manner. For example, 
-arrestin-1 mediates recruitment of Mdm2 to activated insulin-like growth factor-
1 receptor (IGF-1R) (Girnita et al., 2003; Girnita et al., 2005). Mdm2 poly-
ubiquitinates IGF-1R and promotes its degradation. Mdm2 also poly-ubiquitinates 
and targets for degradation the G-protein-coupled receptor kinase 2 (GRK2), an 
attenuator of GPCRs and other receptors, including IGF-1R (Salcedo et al., 
2006). Additionally, Mdm2 mediates poly-ubiquitination of phosphodiesterase-
4D5 (PDE4D5) (Li et al., 2009). -arrestin interacts with PDE4D5 following 
receptor activation, leading to localized hydrolysis of the second messenger 
cAMP (Baillie et al., 2005). Poly-ubiquitination of PDE4D5 is transient, and 
occurs shortly after receptor stimulation, promoting its interaction with -arrestin. 
Poly-ubiquitination of -arrestin, on the other hand, takes place at a later time, 
inhibiting its interaction with PDE4D5. Thus, Mdm2 is involved in multiple 
functions of -arrestin-mediated signal transduction. 
 E2F family transcription factors are regulators of cell cycle genes. E2Fs 
are primarily regulated by their inhibitory binding partner pRb (though some 
family members are pRb independent), which becomes phosphorylated by 
cyclin-dependent kinases (CDKs) leading to its dissociation from E2Fs, allowing 
them to trans-activate their targets (reviewed by Chen et al., 2009). The p53 
target gene p21 encodes a CDK inhibitor, and thus links p53 to the pRb pathway. 
However, the links between the two pathways are much more complex, with pRb, 
p53, Mdm2 and ARF forming a network of binding interactions affecting each 
other’s activities (Polager and Ginsberg, 2009). Mdm2 interacts with E2F1 and 
stimulates the transcriptional activity of E2F1 and its binding partner DP1 (Martin 
et al., 1995). Moreover, Mdm2 mediates E2F1 activation through interacting with 
the E2F1 inhibitor pRb, in a p53-independent manner (Sdek et al., 2004; Xiao et 
al., 1995), and targeting pRb for degradation (Sdek et al., 2005). ARF over-
expression leads to higher levels of pRb, suggesting ARF inhibits Mdm2-
mediated pRb degradation (Sdek et al., 2005). Interestingly, Mdm2 was also 
shown to promote E2F1 degradation (Loughran and La Thangue, 2000), under 
conditions in which E2F1 normally induces apoptosis. 
Recently Mdm2 was reported to influence transcription by affecting protein 
folding. Mdm2 possesses an ATP binding activity through the P-loop motif within 
its RING domain (Poyurovsky et al., 2003; Priest et al., 2010). Mdm2 functions as 
a chaperone towards p53 and E2F1 and this activity is influenced by ATP binding 
in the following manner. ATP binding to Mdm2 stimulates p53 folding into a DNA 
binding-competent form (Wawrzynow et al., 2007). E2F1, on the other hand, is 
misfolded in response to Mdm2 ATP binding and thus its DNA binding activity is 
reduced. Although E2F1 is an in vitro ubiquitination target of Mdm2, this activity 
of Mdm2 is not involved in the chaperone function (Stevens et al., 2008). 
 Current mouse models do not support a cell cycle regulation role for 
Mdm2 and MdmX independent of p53 in untransformed cells (Marine et al., 
2006). It would be interesting to examine Mdm2 and MdmX’s effects on cell cycle 
progression in mouse models of cancers over-expressing either Mdm protein, as 
often occurs in cancers, while examining p53 dependence. 
Regulation of mRNA stability and translation 
 The Mdm2 RING domain was shown to specifically interact with RNA in 
vitro in 1996 (Elenbaas et al., 1996). However, we are just beginning to discover 
which mRNA transcripts Mdm2 interacts with in the cell and what the biological 
consequences of such interactions are.  Mdm2 has been shown to affect the 
stability and/or translation of a growing number of mRNA transcripts that will be 
discussed below.  
The p53 mRNA was the first transcript discovered to be regulated by 
Mdm2. The Mdm2 binding domain-encoding sequence in the p53 mRNA 
interacts with Mdm2, leading to enhanced translation of p53 as well as inhibition 
of Mdm2 E3 ligase activity. The enhancement of translation does not depend on 
Mdm2’s E3 ligase activity since an inactive Mdm2C464A enhanced p53 translation 
almost as well as WT Mdm2 (Candeias et al., 2008). In a follow-up study, Gajjar 
and co-authors recently showed that the p53 mRNA:Mdm2 interaction depends 
on ATM-mediated phosphorylation of Mdm2 at Ser395 and contributes to p53 
induction following DNA damage (Gajjar et al., 2012). Its importance was 
exemplified by the discovery that while Mdm2 siRNA increases apoptosis in 
unstressed conditions, it actually protects them from undergoing apoptosis 
following DNA damage in an ATM-dependent manner. Interestingly, the mRNA 
sequence encoding the Mdm2 binding domain is the same sequence that 
interacts with Mdm2, and the Mdm2 domain that binds the p53 mRNA is the 
RING finger domain, that is responsible for ubiquitinating p53. This suggests the 
two functions of Mdm2 in the regulation of p53 may have co-evolved in p53 and 
Mdm2 (Naski et al., 2009). 
 Mdm2 regulates p53 mRNA through an additional, indirect mechanism, 
mediated by the ribosomal protein L26. L26 interacts with the 5’-UTR of the p53 
mRNA and augments its translation (Takagi et al., 2005). However, under 
unstressed conditions Mdm2 ubiquitinates L26 and targets it for degradation. 
Furthermore, the Mdm2 acidic domain interacts with L26 and prevents it from 
binding and augmenting translation of p53 mRNA. Following DNA damage this 
inhibition is relieved, and L26 is free to augment p53 translation (Ofir-Rosenfeld 
et al., 2008). 
 Another mRNA regulated by Mdm2 is the X-linked inhibitor-of-apoptosis 
protein XIAP. XIAP inhibits caspases 3, 7 and 9 (Riedl et al., 2001; Scott et al., 
2005; Shiozaki et al., 2003), the caspases responsible for initiating apoptosis in 
response to cellular stress via the intrinsic pathway (Kuida et al., 1998; Lakhani 
et al., 2006). Transfected Mdm2 leads to increase in XIAP protein levels (Gu et 
al., 2002b). The XIAP mRNA contains an internal ribosome entry site (IRES) in 
its 5’-UTR (Holcik et al., 1999). Mdm2 interacts with the XIAP IRES through its 
RING domain, and enhances its translation. Importantly, cancer cells over-
expressing Mdm2 are resistant to IR-induced apoptosis, which is dependent on 
the Mdm2:XIAP IRES interaction but independent of p53, as it was observed in 
p53 null cells (Gu et al., 2009).  
 MYCN is a gene often amplified in neuroblastoma, and is associated with 
poor prognosis (Brodeur et al., 1984; Seeger et al., 1985). Mdm2 is also often 
amplified in neuroblastomas (Corvi et al., 1995), and was shown to be a direct 
transcriptional target of MYCN in this tumor type (Slack et al., 2005). Forming a 
positive feedback loop, Mdm2 interacts with the MYCN mRNA and leads to its 
stabilization (Gu et al., 2011). More specifically, the stabilization of MYCN mRNA 
is mediated by the Mdm2 RING domain interaction with AU-rich elements within 
the 3’-UTR of MYCN mRNA, and correlates with increased translation of MYCN. 
In contrast to Mdm2’s regulation of XIAP, however, Mdm2 does not regulate 
IRES-dependent translation of MYCN and the enhanced translation seems to be 
a result of the increased stability. Knockdown of Mdm2 in neuroblastoma cells 
down-regulates MYCN and inhibits colony formation, while not activating p53, 
and also protects p53 null neuroblastoma cells from resistance to IR (Gu et al., 
2011).  
 The vascular endothelial growth factor (VEGF) is an important inducer of 
angiogenesis, and is essential for solid tumor development (Kim et al., 1993). 
The Mdm2 RING domain interacts with VEGF 3’-UTR and increases its stability, 
leading to increased levels of VEGF protein, similarly to its regulation of MYCN. 
In a xenograft mouse model, knockdown of Mdm2 in p53-null neuroblastoma 
cells reduces tumor size and microvessel density (Zhou et al., 2011). A possible 
involvement of Mdm2’s regulation of MYCN in the xenograft experiment was not 
addressed by the authors.  
 There are still many unanswered questions regarding Mdm2’s regulation 
of mRNA stability and translation. The precise mechanisms of action are not 
delineated yet. More globally, an RNA immunoprecipitation followed by a 
microarray analysis may give us a larger picture of the transcripts bound and 
potentially regulated by Mdm2.  
 MdmX has not been shown as of yet to be regulating mRNAs, but a 
thorough examination has not been carried out. Since Mdm2’s RING domain is 
the primary region regulating mRNAs, it is possible that MdmX carries out similar 
functions considering the high degree of similarity between the two RING 
domains, and the fact that both RING domains bind nucleotides with similar 
affinity and specificity (Poyurovsky et al., 2003; Priest et al., 2010). 
 
Mdm2 as a transcription cofactor 
 Evidence collected over the past years suggests that Mdm2 itself can 
affect transcription, both in a p53-dependent and independent manner. Early on, 
it was shown in an in vitro transcription system that Mdm2 fused to a 
heterologous DNA binding domain represses transcription (Thut et al., 1997). A 
region between aa 50-222 is required for this inhibition and directly interacts with 
basal transcription machinery components (TFIIE and TBP) in a p53-independent 
manner.  
Thut and co-authors studied a truncated form of Mdm2 aa 1-324 in their 
report described above. In another study, a heterologous DNA binding domain 
(Gal4) fused to full-length Mdm2 confirmed repression of p53 independent 
transcription of a luciferase reporter. However, in this study, Mdm2 RING domain 
deletion abolished the repressive ability of Mdm2 (Minsky and Oren, 2004). 
These data suggest that Mdm2 can function as a co-repressor if recruited to a 
promoter via its interaction with p53 as well as with other transcription factors that 
may possess DNA binding activity and can interact with Mdm2. Taken together, 
these studies suggest that there may be two independent domains in Mdm2 that 
are involved in transcriptional repression: one that resides within amino acids 50-
222 and another within the RING domain. 
 In a more physiological system, Mdm2 was indeed shown to interact with 
chromatin. Chromatin immunoprecipitation (ChIP) in cells over-expressing Mdm2 
(Jin et al., 2004; Ohkubo et al., 2006; Tang et al., 2008) as well as in cells with 
high (Arva et al., 2005; Minsky and Oren, 2004) or normal (White et al., 2006) 
levels of endogenous Mdm2 demonstrated that Mdm2 can be detected on p53 
target gene promoters. The association of endogenous Mdm2 with p53 REs is 
p53 dependent, as Mdm2 was not detected on the tested gene promoters in cells 
lacking p53 (White et al., 2006). Further supporting this observation, Mdm2 was 
shown to co-localize with p53 on the p21 gene promoter in a sequential ChIP 
experiment (first immunoprecipitating p53, and then Mdm2 from the first eluate) 
(Minsky and Oren, 2004). Following DNA damage, Mdm2 dissociates from p53 
target gene promoters (Tang et al., 2008; White et al., 2006). A global Mdm2 
ChIP, however, has not been performed. Hence, we cannot conclude whether 
Mdm2 localization to chromatin is solely a p53-dependent event. 
 Chromatin bound Mdm2 may suppress p53 through multiple mechanisms. 
As described above, the classical model for Mdm2 inhibiting p53 transcription is 
through inhibiting its TA domain from recruiting transcriptional co-activators. 
Additionally, Mdm2 can recruit transcriptional co-repressors as well as attach 
ubiquitin moieties to histones, modifying the chromatin state at its vicinity. 
 Mdm2 forms a complex with SUV39H1 and EHMT1 histone methyl 
transferase proteins that catalyze the repressive histone H3 Lys9 (H3K9) 
methylation (Chen et al., 2010). Mdm2 recruits SUV39H1 and EHMT1 to p53, 
forming a complex that possesses H3K9 methylation ability in vitro. Interestingly, 
H3K9 methylation of the p53 target promoters p21 and PUMA is increased 
following activation of p53, and Mdm2 expression promotes this modification. 
This suggests that SUV39H1 and EHMT1-mediated H3K9 methylation may play 
a role in the Mdm2:p53 negative feedback loop. ARF interaction with Mdm2 
inhibits interaction with SUV39H1 and EHMT1, suggesting that oncogenic stress 
regulates Mdm2-interaction with histone methyl transferases. It is interesting to 
note, that MdmX does not interact with SUV39H1 and EHMT1 (Chen et al., 
2010). Whether Mdm2 associates with chromatin for performing this function 
needs to be directly tested.  
 A more direct function of Mdm2 in influencing gene expression is through 
mono-ubiquitination of histone H2B (Minsky and Oren, 2004). In vitro, Mdm2 
interacts with nucleosomes and catalyzes mono-ubiquitination of histones H2A 
and H2B. In cells Mdm2 does not seem to catalyze H2A modification. It does, 
however, localize with p53 to its response element in the p21 gene, where its 
association promotes mono-ubiquitination of histone H2B. The function of this 
modification is not well understood. While Mdm2 tethered to DNA represses 
basal transcription from a luciferase reporter in a RING-domain-dependent 
manner (Minsky and Oren, 2004), suggesting a repressive role for this 
modification as has been reported in yeast (Sun and Allis, 2002), a global 
analysis of the occurrence of this modification suggests a different role in 
mammals. 
 In a follow-up study, an antibody directed at nomo-ubiquitinated H2B 
(ubH2B) was generated using a branched peptide (Minsky et al., 2008). The 
authors used this antibody for ChIP analysis looking at its global distribution 
along the genome alongside an antibody directed at Histone H3 di-methylated on 
Lys4 (H3K4me2), a modification associated with active transcription, as well as 
an antibody directed at total histone H3. Surprisingly, ubH2B levels correlate with 
actively transcribed genes, starting near the transcription start site and extending 
into the gene, as opposed to H3K4me2, which is highly enriched at the promoter 
region, peaking around 1kb upstream of the transcription start site. A more 
specific analysis of ubH2B distribution along the p21 gene revealed association 
throughout the whole coding region that is stimulated by p53 induction and 
quickly removed when p53 levels are reduced (Minsky et al., 2008). These 
observations suggest that ubH2B modification is a highly dynamic process that is 
associated with actively transcribed genes globally, hinting at a possible role in 
elongation (Minsky et al., 2008). Taken together, the two studies by Minsky and 
co-authors suggest possible positive as well as negative roles for Mdm2 in 
regulating transcription, both mediated by the Mdm2 RING domain. It is important 
to note, however, that Mdm2 is not the primary E3 ligase for H2B. The RNF20/40 
complex is thought to be the main modifier, though BRCA1 can also promote this 
modification (Weake and Workman, 2008).  
In conclusion, Mdm2 and MdmX modulate gene expression through 
multiple ways, with outcomes and mechanisms not fully elucidated. Both global 
approaches for studying the effects of these proteins on gene expression as well 
as biochemical mechanistic studies will help us answer the “what” and “how” 
questions. The answers are likely to be quite complex, as the Mdm proteins 
appear to have tissue-specific effects that may also depend on the 
developmental stage. Future research will very likely reveal new and interesting 




PCNA is a ring shaped DNA sliding clamp composed of three identical 
subunits, which coordinates and affects multiple steps in DNA replication and 
repair, including increasing the processivity of the replicative polymerases, 
preventing DNA reduplication, promoting both error prone trans lesion synthesis 
as well as error free repair of DNA damage (Moldovan et al., 2007). DNA 
replication begins with polymerase  (pol ) which polymerizes an RNA primer 
followed by a short stretch of DNA. PCNA is then loaded by the clamp loader 
replication factor C (RFC) onto the RNA-DNA hybrid, where it promotes 
polymerase switch.  The primase pol  is replaced by the replicative polymerases 
pol  and , whose processivity is enhanced by PCNA (Burgers, 1991). Thus, 
PCNA topologically links the replicative polymerases to DNA, a process that may 
be particularly important for the replication of the short Okazaki fragments on the 
lagging strand. PCNA levels are elevated in many cancers, reflecting its 
importance for DNA replication and cell division, and hence is often used as a 
marker for replicating tumor cells, and in some cancers serves as a prognostic 
marker (Caputi et al., 1998; del Giglio et al., 1992). Although PCNA’s roles in 
coordinating DNA replication and repair are regulated in part by post-translational 
modification, no cancer associated PCNA protein species were identified 
(Naryzhny and Lee, 2007). 
PCNA interacts with a large array of partner proteins (Maga and 
Hubscher, 2003; Naryzhny, 2008), which bind PCNA primarily through their 
PCNA interacting protein (PIP) motif (Xu et al., 2001). Theoretically, each PCNA 
trimer could interact with three different partners, and the partners can compete 
for PCNA binding, with some interactions controlled by post-translational 
modifications (Maga and Hubscher, 2003; Stoimenov and Helleday, 2009).  
p53 interacts with and activates the PCNA promoter in response to stress 
(Shan et al., 2003; Shivakumar et al., 1995; Xu and Morris, 1999), but also p53 
over-expression or activation correlates with PCNA mRNA down-regulation 
(Mercer et al., 1991; Yamaguchi et al., 1994). A reconciling explanation to the 
opposite effects of p53 activation on PCNA gene expression is provided by the 
observation that the PCNA gene is regulated by the cell cycle, with an 
accumulation of both protein and mRNA at the G1/S transition and early S 
phase, which decrease thereafter during G2 and M phases (Almendral et al., 
1987; Bolton et al., 1992; Gazitt et al., 1993; Kurki et al., 1986; Stewart and 
Dell'Orco, 1992). The cell cycle-regulated transcription factor E2F, which 
activates many genes required for S phase, also activates the PCNA promoter 
(Li et al., 2003; Tommasi and Pfeifer, 1999). The p53 target CDK-inhibitor p21 
mediates cell cycle arrest and inhibits E2F-mediated transcription through two 
ways. Indirectly, through p21’s inhibition of CDKs and directly, by interacting with 
E2F (Dotto, 2000). Thus, p21 mediates transcriptional repression in response to 
p53 activation (Lohr et al., 2003). p53 may, therefore, repress the transcription of 
PCNA through the activation of p21. 
PCNA is linked to the p53 pathway in multiple ways. p53, Mdm2 (Banks et 
al., 2006) and p21 (Waga et al., 1994; Warbrick et al., 1995) contain a PIP motif 
and were shown to interact with PCNA. PCNA loss was shown to lead to p53 
stabilization (Banks et al., 2006), while Mdm2 mediates poly-ubiquitination and 
proteasomal degradation of PCNA (Groehler and Lannigan, 2010). p21’s effects 
on PCNA are well studied and have been recently reviewed (Livneh, 2006; 
Prives and Gottifredi, 2008; Soria and Gottifredi, 2010). The C-terminal PIP 
domain of p21 has the highest affinity to PCNA of all tested proteins (Bruning and 
Shamoo, 2004), and can compete off many factors, including pol  (Oku et al., 
1998). Thus, p21 interacts with PCNA and inhibits DNA replication but, 
interestingly, not nucleotide excision repair (NER) (Chen et al., 1995; Li et al., 
1994; Luo et al., 1995; Shivji et al., 1994). Although at high levels p21 may inhibit 
NER as well (Stoyanova et al., 2008). Additionally, p21 plays a key role in the 
inhibition of the error prone trans lesion synthesis (Livneh, 2006; Prives and 
Gottifredi, 2008). 
The PCNA promoter is regulated by multiple factors (Fig. 1.2). (1) E2F 
sites are present both in intron 1 (+583) and in the upstream promoter region 
( 86 to 75), and were shown to be important for PCNA expression at the 
beginning of S phase as well as in response to serum stimulation. (2) The 
adenovirus 243 amino acid E1A oncoprotein activates PCNA via the PCNA E1A-
responsive element (PERE) (nucleotides 59 to 45). PERE contains consensus 
sequences recognized by a complex containing activating transcription factor 
(ATF), the Hepatitis virus B enhancer-associated protein (RFX1) and cAMP 
response element-binding protein (CREB) (Labrie et al., 1995; Liu et al., 1999; 
Morris and Mathews, 1991). (3) CTF site (nucleotides 99 to 95). (4) An SP1 
site (nucleotides 191 to 186) (Wang et al., 2000). (5) A p53 RE (nucleotides -
217 to -236) (Morris et al., 1996). A reporter assay analysis mutating 17 putative 
transcription factor response elements in the PCNA promoter identified E2F as 
being responsible for cell cycle regulation of the PCNA gene (Li et al., 2003). 
PCNA is not only controlled by the cell cycle, but it is also required for its 
progression, and thus regulates entry into S phase. PCNA down-regulation by 
siRNA or shRNA leads to inhibition of DNA synthesis and cell cycle arrest at the 




It is becoming clear that Mdm2 and MdmX affect p53 in ever more 
complex ways. The early view, that they target p53 for degradation and inhibit it 
transcriptionally in a non-discriminatory way is changing. Experiments in mice, in 
cell culture and in vitro with purified components show specific effects of Mdm2 
and MdmX on p53 function, influencing the outcomes of p53 activation. While 
some of the underlying mechanisms begin to be uncovered, there is still a long 
way to go.  
This thesis focuses on the roles of MdmX and Mdm2 in the activation of 
p53 target genes. In particular, my work has examined Mdm2 and PCNA in this 
regard. We show that Mdm2 requires MdmX for its full activation by p53 following 
DNA damage, and that PCNA gene activation is affected by Mdm2 and MdmX 
and correlates with cell cycle arrest. 
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ABSTRACT 
The activity of the tumor suppressor p53 is tightly controlled by its main negative 
regulator Mdm2, which inhibits p53’s transcriptional activity and targets it for 
degradation via the proteasome pathway. The closely related Mdm2 homolog, 
MdmX, is also considered to be a general inhibitor of transactivation by p53, 
through binding to the p53 activation domain. We show here that, unexpectedly, 
upon DNA damage and ribosomal stress, MdmX plays a positive role in p53-
mediated activation of the Mdm2 gene, but not of numerous other p53 target 
genes including p21. Down-regulation of MdmX results in lower levels of mature 
and nascent Mdm2 transcripts following cellular stress. This correlates with a 
longer p53 half-life following DNA damage. In vitro, Mdm2 inhibits the binding of 
p53 to DNA to a much greater extent than does MdmX, although MdmX does not 
stimulate p53 interaction with Mdm2 promoter DNA. Strikingly, however, MdmX 
is required for optimal p53 binding to the Mdm2 promoter in vivo. Thus, we have 
described a new mechanism by which MdmX can suppress p53, which is through 
transcriptional activation of p53’s principal negative regulator, Mdm2. 
INTRODUCTION 
The tumor suppressor p53 is a transcription factor that responds to cellular 
stress conditions such as DNA damage, ribosomal stress and oncogene 
activation by regulating the expression of key target genes. This leads to various 
cellular outcomes, including cell cycle arrest, apoptosis and senescence 
(Vousden and Prives, 2009). As important as the activation of these processes 
upon damage is for tumor suppression, it is crucial that their induction is inhibited 
in normal unstressed growth conditions. 
p53 is mutated in over 50% of cancers and other aspects of its network in 
the remaining group are deregulated frequently via amplification and over 
expression of Mdm2 and MdmX (Manfredi, 2010; Momand et al., 1998; Oliner et 
al., 1992). p53 is normally inhibited by its principal negative regulator, Mdm2, 
through multiple mechanisms. Mdm2 prevents recruitment of transcriptional co-
activators to target promoters by binding to the p53 activation domain (Oliner et 
al., 1993). Furthermore, Mdm2 is an E3 ubiquitin ligase and it promotes p53 poly-
ubiquitination and degradation through the ubiquitin-proteasome pathway (Haupt 
et al., 1997; Honda et al., 1997). MdmX, a structural homolog of Mdm2, also 
functions as a negative regulator of p53-mediated transcription (Shvarts et al., 
1996; Stad et al., 2000). However, unlike Mdm2, the MdmX RING domain does 
not possess detectable E3 ligase activity (Stad et al., 2000). The importance of 
both Mdm2 and MdmX in negative regulation of p53 was demonstrated in mice, 
where homozygous deletion of either Mdm gene leads to embryonic lethality 
unless p53 is co-deleted, suggesting non-redundant functions of the two proteins 
in p53 inhibition during development (Jones et al., 1995; Migliorini et al., 2002; 
Montes de Oca Luna et al., 1995; Parant et al., 2001). 
Following DNA damage, p53, MdmX and Mdm2 undergo multiple post-
translational modifications leading to Mdm2-mediated ubiquitination and 
degradation of MdmX in nuclei (Chen et al., 2005; Jin et al., 2006; Kawai et al., 
2003; Okamoto et al., 2005; Pan and Chen, 2003; Pereg et al., 2005; Wang et 
al., 2007) as well as stabilization and activation of p53. Additionally, these 
modifications contribute to p53 target gene selectivity (reviewed by Kruse and 
Gu, 2009; Wade et al., 2010). How p53 chooses its target genes is an actively 
studied and still open question. In addition to p53 modifications, target gene 
promoter architecture and p53 differential protein binding or co-factor recruitment 
have been reported to affect the transcriptional outcome of p53 activation 
(Murray-Zmijewski et al., 2008; Riley et al., 2008; Vousden and Prives, 2009). 
This suggests that different p53 target genes may require a particular 
combination of transcriptional activators and a specific modification state to be 
activated. 
One unique target of p53 is the Mdm2 gene itself, thus forming a negative 
feedback loop upon p53 activation. Mdm2 is controlled by two promoters: the P1 
promoter, which is constitutively active in most cells, though at low levels, and 
the p53 responsive P2 promoter, located within Mdm2’s first intron, adjacent to 
its transcription start site (Barak et al., 1994). The Mdm2 P2 promoter contains 
two p53 binding sites, and is activated by p53 in response to various cellular 
stresses (Wu et al., 1993).  
In this study, we have examined the effects of MdmX on the transcription 
of p53 target genes. We found that full expression of MdmX is necessary for 
enabling p53 to activate Mdm2 maximally following stress in multiple cell lines 
(although some tested cell lines did not display this phenotype). We further 
investigated the mechanism by which MdmX exerts this effect, and showed that 
MdmX enhances p53 binding to the Mdm2 promoter in cells after stress. The 
defect in Mdm2 activation following MdmX down-regulation results in prolonged 
p53 stability at times when the cellular p53 response normally decreases. Thus, 
we have identified a novel mechanism through which MdmX represses p53, by 
promoting the activation of its chief inhibitor, Mdm2. 
 
MATERIALS AND METHODS 
Cell culture. MCF7, U2OS and SK-HEP-1 cells were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. 
Drug treatments were as follows: neocarzinostatin (300 ng/mL, Kayaku Co., 
Tokyo, Japan) was added for 4 hr or as indicated, while 5-fluorouracil (500 nM, 
Sigma-Aldrich, St Louis, MO, USA), actinomycin D (4 nM, Calbiochem, San 
Diego, CA, USA) and doxorubicin (100 nM, Sigma-Aldrich, St Louis, MO, USA) 
were administered for 8 hr. Cycloheximide (100 g/mL, Sigma-Aldrich, St Louis, 
MO, USA) was given to cells for the times indicated, and Nutlin-3 (10 M, Sigma-
Aldrich, St Louis, MO, USA) was administered for 16 hr. 
 
Transfection. siRNA duplexes were obtained from Qiagen (Valencia, CA, 
USA) and Invitrogen (Carlsbad, CA, USA) and transfected into cells with 
DharmaFECT 1 reagent (Dharmacon, Thermo Fisher Scientific, Lafayette, CO, 
USA) for 48 hr. siRNA sequences were as follows: The sequences directed 
against luciferase (siLuc) (Urist et al., 2004) and siRNA directed against MdmX 
(siMdmX) (Chen et al., 2005) were published previously. siMdmX #2 refers to 
Hs_MDM4_4 FlexiTube siRNA (QIAGEN, Valencia, CA, USA), For siMdmX #3, 
the sense strand was AGGAUCACAGUAUGGAUAUUU, while the antisense 
strand was AUAUCCAUACUGUGAUCCUGU. For siMdmX #4, the sense strand 
was GGAUAUUCCAAGUCAAGACUU, while the antisense strand was 
GUCUUGACUUGGAAUAUCCAU. 
 
Quantitative reverse transcription polymerase chain reaction 
analysis (qRT-PCR). RNA was isolated from cultured cells using the QIAGEN 
RNeasy Mini kit and reverse transcribed into cDNA with QuantiTect Reverse 
Transcription kit (QIAGEN, Valencia, CA, USA). PCR was performed with either 
Prism 7300 or StepOnePlus Real-Time PCR system using Power SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Relative mRNA 
levels were calculated using the Ct method, normalized first to the levels of 
control RPL32 mRNA, and then to the levels of the plotted mRNA in untreated 
siLuc control sample. Primer sequences are available upon request. Graphs are 
representative of multiple independent experiments, with error bars representing 
technical PCR replicates. 
 
Immunoblot analysis (Western blot). Whole cell lysates were analyzed 
by standard immunoblotting procedure as described (Urist et al., 2004). Briefly, 
cells were harvested by scraping in PBS and lysed in TEGN buffer (10 mM Tris 
at pH 8, 1 mM EDTA, 10% glycerol, 0.5% NP40, 400 mM NaCl) supplemented 
with protease inhibitors, incubated on ice for 20 minutes and cleared by 
centrifugation (13,000 rpm for 10 min at 4ºC). Total protein concentration was 
measured using the Bio-Rad Protein Assay (Life Science Research, Hercules, 
CA, USA). Equal amounts of total protein were separated on 9% polyacrylamide 
gel and transferred to a nitrocellulose membrane, which was then blocked for 1 
hr in PBS containing 0.1% Tween-20 (Sigma-Aldrich, St Louis, MO, USA) and 
5% non-fat dry milk. Commercially obtained antibodies used in this study were 
MdmX A300-287A (Bethyl laboratories, Montgomery, TX, USA); MdmX (G-10) 
sc-74467, p21 (C-19) sc-397 and Mdm2 (N-20) sc-813 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA).  The following mouse monoclonal 
antibodies were used as hybridoma supernatants: p53 (DO-1, 1801) and Mdm2 
(3G5, 5B10, 4B11). 
Immunoprecipitation (IP) Assay. Cells were harvested by scraping in 
PBS, lysed in low salt IP buffer (25 mM Tris-HCl pH 7.5, 137 mM NaCl, 2.7 mM 
KCl and 0.5% Nonidet P-40) and cleared by centrifugation (13,000 rpm for 10 
min at 4ºC). Total protein concentration was measured using the Bio-Rad Protein 
Assay (Life Science Research, Hercules, CA, USA). All the following steps were 
performed at 4ºC. One mg total protein was taken for each immunoprecipitation 
sample, and pre-cleared by rocking with 20 L protein G beads (GE healthcare, 
Little Chalfont, UK) for 1 hr. Purified monoclonal p53 antibody (1801; 2 μg) was 
added to the pre-cleared lysate and rocked for 2 hr. Protein G beads (35 L) that 
were blocked over night in IP buffer containing BSA (1 mg/mL, New England 
Biolabs, Ipswich, MA, USA), were added for an additional 1 hr incubation. 
Following 4 washes with IP buffer, Protein Sample Buffer was added and 
proteins were eluted by incubation at 95ºC for 10 min. Immunoblot analysis was 
performed as described above. 
 
Chromatin Immunoprecipitation (ChIP). Chromatin immunoprecipitation 
was performed as described previously (Beckerman et al., 2009; Gomes et al., 
2006). Cells were cross-linked in PBS containing 1% formaldehyde for 15 min 
and quenched with glycine (125 mM final concentration) for 5 min at RT. 
Following 2 washes with ice cold PBS the cells were harvested in PBS by 
scraping. All the following steps were performed at 4ºC. Cell lysis was performed 
using RIPA buffer (150 mM NaCl, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-
HCl pH 8, 5 mM EDTA) supplemented with protease inhibitors. The DNA was 
then sheared by sonication to fragments of approximately 500 bp and lysates 
were cleared by centrifugation (13,000 rpm for 10 min at 4ºC). Total protein 
concentration was measured using the Bio-Rad Protein Assay (Life Science 
Research, Hercules, CA, USA) and samples were normalized to ensure equal 
amounts of protein. The samples were pre-cleared for 1 hr with a mixture (15 L) 
of protein A (Thermo Scientific, Hudson, NH, USA) and protein G (GE 
healthcare, Little Chalfont, UK) beads. Immunoprecipitation was performed 
overnight with mixed protein A/G beads (35 L) that were blocked overnight at 
4ºC with RIPA buffer containing 1 mg/mL BSA (New England Biolabs, Ipswich, 
MA, USA) and 0.3 mg/mL Salmon Sperm DNA (Invitrogen Corporation, 
Carlsbad, CA, USA). For p53 ChIP experiments, the beads were incubated for 4 
hr with anti-p53 DO-1/1801 hybridoma supernatant mixture and washed 3 times 
in RIPA buffer. For MdmX ChIP experiments (and IgG controls) blocked beads 
were added to the lysates together with either MdmX A300-287A (Bethyl 
laboratories, Montgomery, TX, USA) or mouse IgG (Sigma-Aldrich, St Louis, MO, 
USA). Eight washes were performed, with 5 min rocking between each wash. 
The beads were first washed twice with RIPA buffer, then 4 times with ChIP 
wash buffer (100 mM Tris-HCl pH 8.5, 500 mM LiCl, 1% Nonidet P-40, 1% 
deoxycholic acid), followed by additional two washes with RIPA buffer. Finally, 
the beads were washed twice briefly with TE (10 mM Tris-HCl pH8, 1 mM 
EDTA). Immuno-complexes were eluted by incubation at 65ºC for 10 min in TE 
supplemented with SDS up to 1%. Cross-linking was reversed by adding NaCl to 
a final concentration of 200 mM and incubating at 65ºC for 5 hr. DNA was 
purified using the QIAquick PCR Purification kit (QIAGEN, Valencia, CA, USA). 
ChIP-enriched DNA was quantitated using either the Prism 7300 or StepOnePlus 
Real-Time PCR system using Power SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA), using the Absolute Quantification method, in 
which ChIP DNA PCR reactions were run alongside a standard curve of genomic 
DNA. Regions amplified included the p53 response elements in the p21 promoter 
and the Mdm2 P2 promoters (Laptenko et al., 2011). For a negative control we 
used a non-transcribed region located within chromosome 5 (Labhart et al., 
2005). 
 
Electromobility Shift Assay (EMSA). EMSA was performed as 
previously published (Lokshin et al., 2007) with the following double stranded 
probes (sense strand presented here): Mdm2: 5’-AGCTGGTCAAGTTCAG 
ACACGTTCCGAAACTGCAGTAAAAGGAGTTAAGTCCTGACTTGTCTCCAG-3’; 
p21 5’-TCAGGAACATGTCCCAACATGTTGAGCTCTGGCATAGAAGAGGCTGG 
TGGCTATTTTGTCCTTGGG-3’; p21 mutant competitor 5’-TCAGGAAtATaTC 
CcAAtATaTTgAGCTCTGGCATAGAAGAGGCTGGTGGCTATTTTGTCCTTGGG 
(mutated residues are in lower case). p53 (50 ng) was pre-incubated with mutant 
p21 oligonucleotide and Mdm2 or MdmX (0-400 ng as indicated) in EMSA buffer 
(12.5 mM Tris-HCl pH 6.8, 25 mM KCl, 10% glycerol, 0.05% Triton-X 100, 0.5 
mg/mL BSA, 1 mM DTT) for 20 min. 32P-end labeled Mdm2 or p21 probe was 
added for 10 min and the protein DNA complexes were resolved on 4% native 
polyacrylamide gels, which were then transferred to a blotting paper, dried and 
quantitated by a Phosphorimager (GE healthcare, Little Chalfont, UK), and 
analyzed by ImageQuant software (GE healthcare, Little Chalfont, UK). 
 
Protein Purification. MdmX and Mdm2 proteins were purified from 
baculovirus-infected insect cells as described before (Zhu et al., 2009). Insect 
Sf9 cells were infected with recombinant baculovirus expressing Flag-Mdm2 or 
HA-MdmX. Cells were lysed by sonication in buffer A (50 mM Tris-HCl pH 8, 150 
mM NaCl, 10% glycerol) supplemented with protease inhibitors and cleared by 
centrifugation. Flag-Mdm2 was incubated with anti-Flag M2 Affinity Gel (Sigma-
Aldrich, St Louis, MO, USA) and HA-MdmX was incubated with Anti-HA Affinity 
Matrix (Roche, Indianapolis, IN, USA). The beads were then washed in high salt 
buffer A containing 300 mM salt. Flag-Mdm2 was eluted with 1 mg/mL Flag 
peptide (Sigma-Aldrich, St Louis, MO, USA) in buffer A. HA-MdmX was eluted 
with 1 mg/mL HA peptide (Roche, Indianapolis, IN, USA) at 30ºC. His-p53 protein 
was purified from E. coli as published previously (Shieh et al., 2000). BL21 E. coli 
cells were transformed with His-p53 expression vector and induced with IPTG for 
2 hr at RT. Cells were lysed by one freeze-thaw cycle followed by sonication in 
lysis buffer (0.3 M NaCl, 50 mM NaH2PO4  pH 8, 20% glycerol, 1% Nonidet P-40, 
10 mM -mercaptoethanol, 0.5 mM PMSF). Lysates were cleared by 
centrifugation and supernatant loaded onto Ni-NTA column (QIAGEN, Valencia, 
CA, USA). The column was washed with lysis buffer lacking Nonidet P-40, 
supplemented with 40 mM imidazole, and protein was eluted with 0.25 M 
imidazole followed by dialysis for 30 min in storage buffer (20 mM Tris pH 8, 0.2 
mM EDTA, 20% glycerol, 0.5 mM DTT, and 0.5 mM PMSF). 
  
Avidin Biotin Complex DNA (ABCD) assay. ABCD assay conditions 
were modified from published protocol (Daitoku et al., 2003) and performed as 
follows. Cells were harvested by trypsinization, lysed by sonication in C/M buffer 
(25 mM Hepes pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 15% glycerol, 0.3% Triton 
X-100), passed through a 0.45 M filter and normalized for equal amounts of 
total protein. Biotinylated DNA probes (103 bp) that span either the p53 response 
element (RE) sequences in the Mdm2 promoter (WT) or one in which the key 
residues in the p53 REs have been mutated (mutant) were prepared by PCR 
using biotinylated forward primers (Integrated DNA Technologies, Inc, Coralville, 
IA), and purified using QIAquick Gel Extraction kit (QIAGEN, Valencia, CA, USA). 
Probe sequences can be found in Supplementary Materials (Supplementary 
Table 2.T1). Dynabeads M-280 Streptavidin (Invitrogen, Carlsbad, CA, USA) 
were pre-incubated with the biotinylated DNA probes in Binding and Washing 
buffer (5 mM Tris-HCl pH 7.5, 500 nM EDTA, 1 M NaCl), according to 
manufacturer’s instructions. The beads were then added to the cell filtrate and 
rocked for 1 hr at 4ºC together with non-biotinylated mutant DNA competitor. 
Following four washes with buffer M (25 mM Hepes pH 7.5, 20% glycerol, 0.4% 
Triton X-100, 0.5 mM EDTA) protein sample buffer was added and boiled for 5 
minutes. Proteins pulled down by the DNA probes were analyzed by the 
immunoblot method.  
 
p53 half-life analysis. Protein levels were quantitated by immunoblot 
analysis using the ODYSSEY system (LI-COR Biotechnology, Lincoln, Nebraska 
USA). Percent protein remaining was calculated, and the data analyzed with 
GraphPad Prism program (GraphPad Software, La Jolla, CA, USA). Statistical 




MdmX ablation has a selective effect on p53 target gene induction 
following multiple forms of cellular stress. To gain insight into the functional 
inhibition of p53 by MdmX, we first determined the impact of MdmX ablation by 
siRNA in MCF7 breast cancer cells. Following introduction of either control 
siRNA or siRNA directed against MdmX, MCF7 cells were either left untreated or 
were treated with the radiomimetic drug Neocarzinostatin (NCS). First, MdmX 
was depleted using two concentrations of siRNA (5 nM and 50 nM) and the 
induction of p53 target genes Mdm2 and p21 was assessed using quantitative 
real time reverse transcription PCR (qRT-PCR) (Fig. 2.1A). Results with p21 
mRNA were as expected: basal levels were up-regulated by MdmX siRNA, while 
levels after NCS treatment were largely unaffected, consistent with the role of 
MdmX as a p53 inhibitor that becomes degraded after DNA damage (Fig. 
2.2.1A). Unexpectedly, however, the opposite response to MdmX depletion was 
seen when we examined Mdm2 induction; its mRNA induction after NCS 
treatment was compromised by MdmX siRNA in a concentration-dependent 
manner (6-fold induction by NCS in control siRNA samples vs. 2-fold induction in 
samples with 50 nM MdmX siRNA), while basal Mdm2 mRNA levels were largely 
unaffected (Fig. 2.1A). Similarly, introduction of MdmX siRNA into either the 
osteosarcoma cell line U2OS (Fig. 2.1B) or the hepatocellular carcinoma cell line 
SK-HEP-1 (Fig. 2.1C) led to reduction of Mdm2 mRNA levels after NCS 
treatment when compared to control siRNA, while p21 levels were either 
increased or unaffected, and p53 protein levels were essentially unchanged by 
the siRNA treatments. Note that in some other tested cell lines (SJSA, WI-38 and 
HepG2) there was no significant effect of MdmX siRNA on Mdm2 expression 
(data not shown), and we cannot conclude that this is a cancer cell-specific 
effect. Importantly, the results were not an off-target effect of the original siRNA 
that we used, because four different siRNA sequences targeting the MdmX 
transcript each behaved identically (Fig. 2.1D). Over-expression of Myc-tagged 
MdmX in MCF7 and U2OS cells, on the other hand, did not affect the expression 
of neither Mdm2 nor p21 regardless of NCS application (Supplementary Fig. 
2.S1).  
 We next examined whether MdmX is required for Mdm2 induction in 
response to p53-inducing cell stressors other than NCS. MCF7 cells were 
transfected with control or MdmX siRNA followed by treatment with NCS, the 
thymidylate synthase inhibitor 5-fluorouracil (5FU), the RNA and DNA synthesis 
inhibitor actinomycin D (ActD), or the topoisomerase II inhibitor doxorubicin 
(Doxo) (Fig. 2.2A). In each case, knockdown of MdmX compromised Mdm2 
mRNA levels while not affecting p21 levels (Fig. 2.2A). Even though p53 levels 
were modestly compromised in the siMdmX-treated cells after some forms of 
stress, as indicated by the lower levels of p53 protein (Fig. 2.2B), these results, 
nevertheless, show that MdmX is required for Mdm2 induction in response to a 
variety of cellular stress signals, including transient DNA damage (NCS), 
prolonged DNA damage (Doxo) and ribosomal stress (5FU and ActD). 
 
MdmX is required for optimal expression of Mdm2 and Wip1, but not 
other tested p53 target genes. We then extended our observation to examine 
the effect of MdmX siRNA on other p53 target genes. MCF7 cells were 
transfected with control or MdmX siRNA and were either untreated or treated 
with NCS for 2 or 4 hr. mRNA levels of a panel of p53 target genes were 
evaluated using qRT-PCR (Fig. 2.3). In untreated cells, following MdmX 
depletion several targets (p21, cyclin G, BAX and PIG3) were induced, while 
others were not (Mdm2, Wip1, 14-3-3  and Noxa). Following NCS treatment, 
however, most target genes (14-3-3 , cyclin G1, BAX, PIG3 and Noxa) behaved 
like the p21 gene, with MdmX not playing a positive role in their expression 
following DNA damage (Fig. 2.3A). Interestingly, like Mdm2, the p53-induced 
phosphatase 1 (Wip1) (Fiscella et al., 1997) required MdmX for optimal induction 
after NCS. Immunoblot analysis confirmed MdmX knock-down was efficient (Fig. 
2.3B). We mention the significance of these findings in the Discussion section. 
 
MdmX siRNA reduces the maximum induction of mature and nascent 
Mdm2 mRNAs. We then tested whether MdmX siRNA affects peak induction of 
Mdm2 transcript levels or, alternately, whether the results were due to change in 
induction kinetics. To approach this problem, we conducted a time course 
experiment where MCF7 cells transfected with control or MdmX siRNA were 
treated with NCS for 0, 2, 4 or 6 hr (Fig. 2.4). In cells containing control siRNA, 
both Mdm2 and p21 were maximally induced 4 hr after NCS. In cells treated with 
siRNA directed at MdmX, Mdm2 also peaked 4 hr post NCS treatment, but the 
peak induction was compromised (~6-fold induction in siLuc samples vs. ~3-fold 
induction in siMdmX samples). p21 mRNA was induced as expected, and its 
peak induction at 4 hr post NCS was unaffected by MdmX siRNA (Fig. 2.4A). In 
agreement with the mRNA data, Mdm2 protein levels were maximally induced 4 
hr after NCS in both control and MdmX siRNA treated cells, but the levels in 
siMdmX treated cells were lower (Fig. 2.4B upper panel). To check whether a 
change in p53 levels may account for the differences in gene expression, we 
quantitated p53 protein levels (Fig 2.4B lower panel). While the Mdm2 mRNA 
levels were reduced by 52% following MdmX siRNA treatment (from 6.53 to 3.16 
relative levels), p53 protein levels were reduced by only 18% (from 2.65 to 2.17 
relative levels), and were thus unlikely to account for our observations. An 
examination of nascent Mdm2 transcript levels by performing qRT-PCR with 
intronic primers confirmed that activation was at the level of transcription and 
showed that maximum induction occurred after 2 hr NCS treatment and was 
reduced in cells transfected with MdmX siRNA (8.5-fold induction in siLuc 
samples vs. 5.5-fold in siMdmX samples) (Fig. 2.4C). These results demonstrate 
that MdmX siRNA compromises the maximal induction of Mdm2 while not 
affecting the kinetics of induction following stress. 
p53 levels increase rapidly after NCS treatment, peaking at 2 hr, and 
sharply decrease thereafter (Fig. 2.4B). Mdm2 and p21 mRNA, however, peak at 
4 hr NCS treatment, coinciding with the time at which MdmX siRNA affects 
Mdm2 mRNA levels (Fig. 2.4A). Therefore, unless stated otherwise, NCS 
treatment in this paper was carried out for 4 hr. Note that at this time point p53 
levels are decreasing and hence the levels may not appear to be induced in 
some cases because p53 protein has returned to or is approaching basal state. 
 
The half-life of p53 after DNA damage is longer in siMdmX-treated 
cells. We next examined the functional consequences of the compromised 
Mdm2 induction following NCS treatment in siMdmX-treated cells. The p53-
Mdm2 feedback loop is essential for turning off the p53 response. We 
hypothesized that the p53 degradation that normally occurs following p53 
activation would be compromised in the presence of MdmX siRNA. To test this, 
we measured p53 stability in the presence of cycloheximide 4 hr after NCS 
application (Fig. 2.5), a time point at which Mdm2 is maximally induced, forming 
the negative feedback, and degrading p53 (Fig. 2.4). Following NCS treatment, 
the calculated p53 half-life was significantly (p < 0.05) longer in cells treated with 
siMdmX (21.7 min) than in control siRNA-treated cells (7.2 min) (Fig. 2.5A). 
MdmX was shown to promote the ubiquitination of p53 by Mdm2 (Kawai et al., 
2007; Okamoto et al., 2009) by altering its substrate specificity. To exclude the 
possibility that this activity of MdmX is responsible for the effect of siMdmX on 
p53 stability after NCS, we calculated the p53 half-life in cells that were not 
treated with NCS. Although we did see a trend in which MdmX siRNA increased 
p53 half-life in untreated cells (about two fold increase, from 22.25 min in siLuc 
cells to 48.08 min in siMdmX compared to three fold increase after NCS), the fold 
difference was lower than in NCS-treated cells, and the effect was not statistically 
significant (Fig. 2.5B). Thus, the effects of MdmX ablation on Mdm2-mediated 
ubiquitination of p53 may contribute to the lower p53 half-life we see after NCS in 
siMdmX-treated cells, but are not the primary mechanism. These data indicate 
that in the absence of MdmX, impaired Mdm2 induction prevents efficient 
functioning of the p53:Mdm2 feedback loop and thereby slows down the 
degradation of p53 as the stress response is being shut off. 
The effect of MdmX on Mdm2 expression does not require the 
Mdm2:p53 interaction. Mdm2 inhibits the interaction of p53 with DNA in vitro 
and in cell culture through its interaction with the C-terminus of p53 (Poyurovsky 
et al., 2010). This raises the possible hypothesis that MdmX functions to activate 
Mdm2 transcription by preventing Mdm2 from inhibiting p53. Therefore, to study 
how MdmX affects p53-mediated transcription of Mdm2 after NCS treatment, we 
examined whether MdmX functions through competing Mdm2 off p53 by testing if 
disruption of the p53:Mdm2 complex alleviates the effects of MdmX siRNA. After 
transfecting MCF7 cells with either control or MdmX siRNA, we pre-treated them 
with Nutlin-3 (Vassilev et al., 2004) for 12 hr to dissociate p53 from Mdm2. We 
then treated the cells with NCS and/or Nutlin-3 for 4 hr and examined mRNA 
levels by qRT-PCR (Supplementary Fig. 2.S2A) and protein levels by Western 
blot (Supplementary Fig. 2.S2B). Mdm2 mRNA levels in control siRNA-treated 
cells were induced 3-fold by NCS, 17-fold by Nutlin-3 and were further increased 
to 24-fold by Nutlin-3 followed by NCS treatment (Nutlin+NCS) (Supplementary 
Fig. 2.S2A). We observed that Mdm2 mRNA levels were reduced by siMdmX in 
Nutlin-3+NCS-treated cells (15% reduction).  This was not the case in cells 
treated with Nutlin-3 alone, where Mdm2 mRNA was slightly elevated by 
siMdmX. With the same trend, siMdmX increased p21 mRNA levels in all 
treatment conditions (Supplementary Fig. 2.S2A). This is expected based on the 
inhibitory function of MdmX on p53-mediated transcription and the reported 
synergism between MdmX siRNA and Nutlin-3 treatment on p53 activation (Hu et 
al., 2006). Although the effect of MdmX ablation on Mdm2 expression in Nutlin-
3+NCS-treated cells was modest, it was statistically significant (p < 0.01) and 
consistently seen in multiple experiments, just as was the failure to see such a 
reduction with p21.  
As further support for Mdm2 not being involved in MdmX’s effect on p53-
mediated Mdm2 transcription, the p53:Mdm2 interaction was not affected by 
MdmX siRNA in a co-immunoprecipitation assay (Supplementary Fig. 2.S2C). 
Equal amounts of Mdm2 were bound by p53 after NCS treatment in both control 
and MdmX siRNA-treated MCF7 cells. Together, these results provide evidence 
that the requirement of MdmX for Mdm2 induction is very likely independent of 
Mdm2’s inhibition of the recruitment of p53 to DNA. 
 
MdmX is not required for p53 interaction with DNA spanning the p53 
binding site from the Mdm2 P2 promoter in vitro. Mdm2 has been shown to 
inhibit the interaction of p53 with DNA by multiple assays (Cross et al., 2011; 
Poyurovsky et al., 2010; Zauberman et al., 1993). We entertained the possibility 
that, in contrast to the inhibitory effect of Mdm2, MdmX might stimulate p53 
binding to DNA sequences within the Mdm2 promoter. Two separate approaches 
were used to determine how Mdm2 and MdmX affect p53 binding to DNA in vitro. 
In the first, we performed an electromobility shift assay with purified components 
in which increasing amounts of either Mdm2 or MdmX protein were added to 
reaction mixtures containing p53 protein and a 66 nucleotide end-labeled probe 
spanning the p53 binding sites in either the p21 or Mdm2 promoter (Fig. 2.6A). 
For each Mdm protein concentration, the p53/DNA complex band intensity was 
normalized to the value of binding of p53 alone (Fig. 2.6A). We confirmed that 
Mdm2 inhibits the p53:DNA interaction. Interestingly, this effect was more severe 
with the Mdm2 probe (60% reduction) than the p21 probe (40% reduction). 
Nevertheless, addition of MdmX also reduced the p53:DNA interaction, albeit to a 
much lesser extent and only at the higher concentrations (20% reduction for both 
probes). This result is in agreement with the recently published observation that, 
as opposed to a co-purified Flag-Mdm2:p53 complex that fails to bind exogenous 
DNA, a Flag-MdmX:p53 complex retains most binding activity (Cross et al., 
2011), but does not support the hypothesis that MdmX is required for full p53 
binding to naked Mdm2 DNA.   
The second approach examined the effect of reducing MdmX levels with 
siRNA on the interaction of p53 with biotinylated DNA probes added to whole cell 
extracts in an Avidin Biotin Complex DNA (ABCD) assay (Daitoku et al., 2003). 
This strategy was taken because we speculated that other factors present in the 
cell extract might influence the ability of p53 to interact with DNA and the effects 
of Mdm2 and MdmX thereon. MCF7 cells were treated with control or MdmX 
siRNA followed by mock or NCS treatment. Cells were then lysed in low salt 
buffer and incubated with Dynabeads pre-bound to DNA containing either wild-
type (WT) or mutated p53 binding sites within the Mdm2 promoter DNA probe as 
indicated. Proteins bound to DNA on beads were visualized by immunoblotting 
(Fig. 2.6B). The conditions of the assay were set such that p53 bound to the DNA 
probes in a strictly sequence-specific manner. Nevertheless, siRNA against 
MdmX did not alter the amount of p53 bound to the WT DNA probe. As a control, 
we showed that under our assay conditions (2 g total protein per reaction), the 
binding capacity of the DNA-bound beads was not reached (Supplementary Fig. 
2.S3). It is also noteworthy that in this assay virtually no detectable Mdm2 or 
MdmX co-bound with p53 to the WT DNA probe. 
Taken together, two different assays showed that neither addition of 
MdmX nor reduction of MdmX levels significantly affected p53 interaction with 
naked DNA. Yet, we showed that MdmX positively affects p53-mediated 
transactivation of the Mdm2 gene. Since these experiments were performed with 
DNA fragments in vitro, we went on to determine whether MdmX might still 
regulate p53 interactions in vivo with intact Mdm2 and p21 promoters present in 
their endogenous locations.  
 
Recruitment of p53 to the Mdm2 promoter is inhibited by MdmX 
siRNA. We used a chromatin immunoprecipitation (ChIP) assay to assess 
whether MdmX is required for recruitment of p53 to the Mdm2 promoter. p53 
recruitment to the Mdm2 and p21 promoters peaks after 90 min of NCS 
treatment (data not shown). MCF7 cells were therefore transfected with control or 
MdmX siRNA, followed by 90 min NCS treatment prior to processing for the ChIP 
assay. Quantitative real time PCR was used to determine the amount of DNA 
bound, amplifying the p53 binding site regions / response elements (REs) from 
the Mdm2 P2 promoter, the p21 5’ RE, and a negative control region 
downstream of the p21 gene (nucleotide position +11,443, data not shown) (Fig. 
2.7). Note that in this experiment as well as the experiments described in Figures 
2.S2C and 2.6B, NCS treatment was performed for 90 min, a time point prior to 
Mdm2 expression, and therefore the impact of MdmX knock-down on Mdm2 
protein levels was not apparent. As expected, p53 binding to both promoters was 
stimulated by treatment with NCS. Remarkably, MdmX siRNA strongly inhibited 
p53 recruitment to the Mdm2 but not to the p21 promoter.  This suggests an 
explanation for the reduced Mdm2 expression seen upon MdmX knock-down:  
impaired p53 recruitment to the Mdm2 promoter in the absence of MdmX results 
in lower Mdm2 mRNA and protein levels while not affecting p21 gene expression. 
This is supported by the observation that Mdm2 mRNA expression correlates 
with p53 interaction with the Mdm2 promoter (Szak et al., 2001). Since we 
observed the effect of MdmX on p53 interaction with DNA in cells and not in vitro, 
we conclude that one or more aspects of the cellular milieu (such as chromatin) 
must be important for the requirement of MdmX for maximal expression of 
Mdm2. 
 
 MdmX preferentially associates with the Mdm2 promoter. One 
possible hypothesis explaining how MdmX affects the recruitment of p53 to DNA 
is that MdmX is bound to the Mdm2 promoter where it may function in recruiting 
p53 or is otherwise facilitating Mdm2 transcription. To assess this possibility, 
MCF7 cells were transfected with control or MdmX siRNA followed by ChIP 
analysis of MdmX or p53 association with the Mdm2 and p21 promoters (Fig. 
2.8). Quantitative PCR of ChIP-enriched DNA showed that indeed significantly 
more MdmX was bound to the Mdm2 promoter than to the p21 promoter (Fig. 
2.8A). On the other hand, a p53 ChIP performed in parallel showed more p53 at 
the p21 promoter than at Mdm2 (Fig. 2.8B). The lower ChIP signal in siMdmX-
treated cells compared to siLuc control confirmed the specificity of the MdmX 
antibody used in the MdmX ChIP (Fig. 2.8C).  This result, while providing only 
correlative support at this point, provides a framework for future investigation of 
the mechanism by which MdmX selectively facilitates Mdm2 transcription in cells 
undergoing genotoxic stress. 
 
DISCUSSION 
To gain more insight into the relationship between p53, Mdm2 and MdmX 
it will be necessary to fully describe the complex interactions between these 
three proteins, and how alterations in levels or activity of each affects p53 
function. The relative levels of Mdm2, MdmX and p53 are critical for their 
function. For example, Mdm2 or MdmX heterozygous mice are viable, but the 
double heterozygotes die in utero and are rescued by deletion of a single p53 
allele (Terzian et al., 2007). Furthermore, alterations in the amount of Mdm2 
protein expressed in mice result in a shift in p53 response, with high Mdm2 being 
permissive to tumorigenesis, normal levels supporting tissue homeostasis, while 
further reductions in Mdm2 levels lead to tumor suppression, tissue-specific 
apoptosis and eventually embryonic lethality due to unleashed p53 activity 
(Mendrysa et al., 2006; Poyurovsky and Prives, 2006). Hence, we set forth to 
examine how altering the levels of MdmX in cells affects the p53 response. Our 
experiments revealed an additional mechanism of p53 regulation by MdmX, in 
which MdmX is required for the activation of Mdm2 and Wip1 expression after a 
variety of cellular stresses (Fig. 2.9).  
It is interesting that of several p53 targets assayed, only Mdm2 and Wip1 
require full expression of MdmX to be induced by p53 in stressed cells. In 
contrast to the great majority of p53 target genes that mediate cellular outcomes 
that are consistent with p53 tumor suppression (cell cycle arrest, death, etc.), 
these two proteins actually serve to restrain and repress p53 functionally.  Mdm2 
is a well described negative regulator of p53 activity and protein levels while 
Wip1, a serine/threonine phosphatase, counteracts p53 by dephosphorylating its 
activators such as ATM and Chk2 among others (Lu et al., 2008). Furthermore, 
like Mdm2 and MdmX, Wip1 is over-expressed in many tumor types (Le 
Guezennec and Bulavin, 2010). Thus, MdmX contributes to the establishment of 
two p53 negative feedback loops: Mdm2-mediated inhibition and degradation of 
p53, and Wip1-mediated down regulation of the cellular stress response (Lu et 
al., 2007). 
p53 recruitment to the Mdm2 promoter after treating cells with NCS is 
reduced in the absence of MdmX. To gain mechanistic insight, multiple 
hypotheses can be considered. First, based on our observation that Mdm2 
inhibits p53 interaction with DNA, an idea supported by previous work (Cross et 
al., 2011; Poyurovsky et al., 2010; Zauberman et al., 1993), we hypothesized that 
MdmX acts in the nucleoplasm to release p53 from Mdm2. If that were the case, 
we would expect to find more p53 bound to Mdm2 in cells treated with MdmX 
siRNA. However, co-immunoprecipitation experiments showed no difference in 
the amount of p53 bound to Mdm2, suggesting this is not likely to be the 
mechanism of action. Alternately, MdmX may function on chromatin, aiding the 
recruitment of p53 to the Mdm2 promoter. Indeed, ChIP experiments showed 
more MdmX bound at the Mdm2 than the p21 promoter.  
How chromatin-bound MdmX would exert a positive effect on p53 binding 
to the Mdm2 promoter, however, is unclear. One possibility could be that a 
specific chromatin structure or modification state renders it accessible to MdmX, 
which would then promote p53 binding to its RE within the region through 
protein-protein interaction. In that regard, some proteins that interact with the p53 
N-terminus (as does MdmX) such as TFIID (Chen et al., 1993) or N-terminal-
specific p53 antibodies (Cain et al., 2000) can stabilize p53 interactions with 
DNA. It is also conceivable that a sub-population of MdmX is recruited to DNA 
together with p53. In this context, it is appealing to hypothesize that MdmX 
influences p53’s selectivity towards interaction with the Mdm2 promoter 
elements, adding MdmX to the collection of p53-binding partners that affect 
promoter selectivity, such as the ASPP family proteins (Beckerman and Prives, 
2010; Samuels-Lev et al., 2001). 
New roles of Mdm proteins in regulation of transcription are continuously 
being uncovered. In addition to regulating transcription through its effects on p53, 
Mdm2 can recruit the co-repressor proteins SUV39H1 and EHMT1 to p53-bound 
promoters, establishing a repressive chromatin state (Chen et al., 2010). Mdm2 
can also bind to p53-responsive promoters and promote mono-ubiquitination of 
histone H2B (Minsky and Oren, 2004; Minsky et al., 2008). This modification was 
recently described to be associated with actively transcribed genes, perhaps 
playing a role in elongation, thus, raising the possibility of Mdm2 functioning as a 
positive as well as negative transcriptional regulator (Minsky and Oren, 2004; 
Minsky et al., 2008). It is therefore not surprising that the Mdm2 gene is regulated 
in multiple ways, and not only by p53.  
The Mdm2 P2 promoter can be regulated by multiple factors. These 
include the estrogen receptor (ER) in ER  positive cell lines (Phelps et al., 2003), 
the thyroid hormone receptor in pituitary cell lines (Qi et al., 1999), the Ras-
induced MAPK pathway (Ries et al., 2000) and TGF  (Araki et al., 2010) 
signaling, all in a p53-independent manner. Furthermore, in MCF7 cells p53 
binding to the Mdm2 promoter does not require the chromatin remodeling protein 
Brg1, while the p21 promoter does (Xu et al., 2007), suggesting a difference in 
the chromatin state between those two promoters, with the chromatin at the 
Mdm2 promoter being relatively open. This agrees with a report showing that in 
the murine embryonic fibroblast cell line 10-1 the Mdm2 locus is constitutively 
nucleosome free (Xiao et al., 1998). We now add MdmX to this list of proteins 
regulating the expression of the Mdm2 gene. What is unique about the Mdm2 
promoter that renders it dependent on such a vast array of regulators is an 
important question in our quest to understand the regulation of stress responses 
and tumor suppression. 
In different mouse models of MdmX knockout (Garcia et al., 2011), MdmX 
RING domain deletion (Pant et al., 2011) or MdmX RING domain mutation 
(Huang et al., 2011), p53 is spontaneously activated. In our system, in 
unstressed cells, following MdmX knockdown, there was selective activation of 
p53 target genes. Specifically, p21, cyclin G1, Bax and Pig3 were induced, while 
Mdm2, Wip1, 14-3-3, and Noxa were not. Interestingly, consistent with our 
observations, Garcia et al. reported activation of subsets of p53 targets in a 
tissue-specific manner (Garcia et al., 2011). The differences in p53 stabilization 
and activation between our experiments in cell lines and the mouse models may 
result in from the contrast between a complete knockout in the mouse versus 
partial knockdown by siRNA. Alternatively, there may be tissue-specific effects or 
perhaps even differences between mice and humans. Nonetheless, these 
studies together suggest that MdmX affects p53 target gene selectivity in a 
complex manner. In this paper, we showed that MdmX is required for Mdm2 
activation after specific cellular stresses in a selection of cell lines. It would be of 
great interest to see whether the same can be observed in conditional MdmX 
knockout mice.  
MdmX is imported into the nucleus following DNA damage (Li et al., 
2002). There it interacts with the RING domain of Mdm2 (Tanimura et al., 1999), 
undergoes ubiquitination by Mdm2 and degradation by the 26S proteasome (de 
Graaf et al., 2003). This sequence of events leaves the unanswered question: 
why would the cell import MdmX into the nucleus following DNA damage? Is it 
solely in order to degrade it? Our work suggests a potential answer to these 
questions by revealing a function MdmX exerts in the nucleus following DNA 
damage: activation of the Mdm2 gene. MdmX seems to exert its function within 
90 min of NCS application, when its effects on p53:DNA binding are observed. 
Due to the complex regulation of MdmX following damage by modifications, sub-
cellular localization and degradation, there seems to be a window in which MdmX 
is modified correctly and is at the right level to exert its function before being fully 
degraded. 
Restoration of the p53 pathway activity in tumors is being actively sought 
through multiple approaches (Brown et al., 2009). For example, the small 
molecule PRIMA-1 restores mutant p53 to wild-type conformation (Bykov et al., 
2002), and both Nutlin-3 (Vassilev et al., 2004) and RITA (Issaeva et al., 2004) 
release p53 from Mdm2. Additionally, a peptide dual inhibitor (PDI) was 
developed to inhibit p53 interaction with both Mdm2 and MdmX (Madden et al., 
2011; Phan et al., 2010), and more recently a specific inhibitor of MdmX 
expression has been identified (Wang et al., 2010). Here we have reported an 
additional layer of complexity in the intricate relationship between Mdm2, MdmX 
and p53. MdmX is required for p53 to interact optimally with the Mdm2 promoter 
after some forms of stress, and to activate transcription of this important p53 
suppressor. With an increased understanding of the p53-Mdm2-MdmX trio, we 
will be able to better predict the effects of such pharmaceutical interventions. 
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FIGURE LEGENDS 
Figure 2.1. MdmX is required for induction of Mdm2 but not p21 after DNA 
damage. 
A. MCF7 cells were transfected with increasing amounts of siRNA to MdmX as 
indicated, balancing total siRNA to 50 nM in all samples with control siRNA (Luc) 
followed by either no treatment (NT) or 4 hr treatment with NCS (300 ng/mL) 
prior to lysis of cells and preparation of RNA for analysis as described in 
Methods. MdmX, Mdm2 and p21 mRNA levels were measured by qRT-PCR and 
graphs show levels of indicated mRNAs relative to values for siLuc controls from 
untreated cells. B. and C. U2OS (B) or SK-HEP-1 (C) cells were transfected with 
50 nM control (Luc) or MdmX siRNA and either untreated (NT) or treated with 
NCS (300 ng/mL) for 4 hr. Bar graphs show Mdm2 and p21 mRNA levels 
measured as in A. Right hand panels show immunoblot analysis of experiment 
shown with antibodies against MdmX, Mdm2, p53, p21 and actin as indicated. D. 
MCF7 cells were transfected with either control (Luc) or 4 different MdmX 
siRNAs  (50 nM each) as in A and either untreated (NT) or treated with NCS (300 
ng/mL) for 4 hr after which mRNA was prepared and quantified by qRT-PCR 
amplifying MdmX, Mdm2 and p21 as in A.  
Figure 2.2. MdmX is required for full induction of Mdm2 after multiple 
cellular stresses. 
A. MCF7 cells were transfected with MdmX siRNA for 48 ours followed by either 
no treatment (NT), treatment for 4 hr with NCS (300 ng/mL), or treatment for 8 hr 
with 5-fluorouracil (5FU, 500 nM), actinomycin D (ActD, 4 nM) or doxorubicin 
(Doxo, 100 nM). p21 (left) and Mdm2 (right) mRNA levels were quantified by 
qRT-PCR analysis. B.  Immunoblot of the experiment in A was performed using 
antibodies against MdmX, p53, Mdm2 and actin. 
 
Figure 2.3. MdmX is required for the induction of Mdm2 and Wip1, but not 
of other tested p53 target genes. 
MCF7 cells were transfected with 50 nM control (Luc) or MdmX siRNA and either 
untreated (0) or treated with NCS (300 ng/mL) for 2 and 4 hr. A. mRNA levels of 
p53 target genes were quantitated by qRT-PCR and averaged over three 
experiments. B. Immunoblot analysis of a representative experiment with 
antibodies against MdmX, Mdm2, p53 and actin.   
 
Figure 2.4. MdmX is required for maximum induction of mature and nascent 
Mdm2 transcripts after NCS but does not affect the kinetics of activation. 
A. MCF7 cells were transfected with MdmX siRNA (50 nM) for 48 hr followed by 
treatment with NCS (300 ng/mL) for the indicated times. Mdm2 and p21 mRNA 
levels were determined using qRT-PCR as in Figure 1. Graphs show qRT-PCR 
amplifying Mdm2 and p21 mRNA. B. Immunoblot analysis of experiment shown 
in A using antibodies against Mdm2, MdmX, p53, p21 and actin (top panel). p53 
protein levels were quantitated using the Odyssey software and levels relative to 
untreated siLuc were graphed (bottom panel) . C. Experiment was performed as 
in A but nascent Mdm2 transcript was measured by qRT-PCR using primers that 
anneal within intron 3 at nt + 2576. 
 
Figure 2.5. Ablation of MdmX extends the half-life of p53 after DNA damage.   
MCF7 cells were transfected with control siLuc or MdmX siRNA for 48 hr and 
then treated with NCS for 4 hr (A) or left untreated (B). Cells were then exposed 
to cycloheximide (100 g/mL) for the indicated times and flash frozen. Protein 
levels were analyzed by immunoblotting for MdmX, p53 and actin as indicated 
(top panel) and quantitated using ODYSSEY software (bottom graph). Graph 
shows percent protein remaining plotted as a function of time based on 3 
independent experiments, and curve was fitted and half-life calculated with 
GraphPad Prism software. Statistical significance was calculated with a student t-
test (p < 0.05).  
 
Figure 2.6. MdmX is not required for p53 binding to DNA in vitro. 
A. Electromobility shift assay (EMSA) was performed with purified components. 
Reaction mixtures containing p53 (50 ng), increasing amounts of Mdm2 or MdmX 
(as indicated in the graphs), and [32P] end-labeled 66 nucleotide double stranded 
DNA probes spanning the p53 REs from either the p21 (p21 probe) or Mdm2 
(Mdm2 probe) promoter sequences were incubated as described in Methods and 
then separated by native PAGE.  Upper panels: Phosphorimager images of the 
up-shifted p53/DNA complexes with the following samples: no p53 control (lane 
1) p53 alone (lane 2), p53 together with a curve of Mdm2 (lanes 3-6), p53 alone 
(lane 7), p53 together with a curve of MdmX (lanes 8-11). Note that Mdm2 and 
MdmX panels are from the same gel. Lower graphs: Quantification of the 
DNA/protein complexes in which the intensity of each up-shifted complex was 
quantitated and relative binding plotted as band intensity normalized to intensity 
of the no Mdm protein band. B. Avidin-biotin complex DNA (ABCD) assay. MCF7 
cells were transfected with control siRNA or MdmX siRNA for 48 hr, followed by 
NCS (300 ng/mL) treatment for 90 minutes. Cells were harvested and lysed in a 
low salt buffer by sonication. Lysates were added to Streptavidin Dynabeads pre-
bound to biotinylated DNA spanning either the wild-type or mutated p53 binding 
sites in the Mdm2 promoter and incubated for 1 hour. Input material and DNA-
bound proteins were resolved on PAGE and identified by immunoblot analysis 
with antibodies against p53, Mdm2, MdmX and actin as indicated. 
 
Figure 2.7. Recruitment of p53 to the Mdm2 promoter in vivo requires 
MdmX.  
Chromatin immunoprecipitation (ChIP) assay. MCF7 cells were transfected with 
control (Luc) siRNA or MdmX siRNA for 48 hr. Cells were then treated with NCS 
for 90 min and subjected to the ChIP protocol as described in Methods. A. ChIP-
enriched DNA was quantitated by real time PCR with primers amplifying Mdm2 
P2 promoter (top panel) or p21 5’ RE (bottom panel). B. Immunoblot of input 
material in a typical experiment using antibodies against Mdm2, MdmX, p53, p21 
and actin as indicated. 
 
Figure 2.8. More MdmX is bound to the Mdm2 promoter than to the p21 
promoter.  
MCF7 cells were transfected with Luc control siRNA (A, B and C) or MdmX 
siRNA (C) for 48 hr. ChIP was performed with antibodies against MdmX (A and 
C), p53 (B) or total mouse IgG (A and B) as indicated. ChIP-enriched DNA was 
quantitated by Real-Time PCR with primers amplifying the p53 REs from the 
Mdm2 or p21 promoters, or a negative control region (control). C. Upper panel: 
Cells containing siLuc (black bars) or siMdmX (white bars) were subjected to 
MdmX ChIP analysis as in A. Lower panel: Immunoblot analysis of input material 
using antibodies against MdmX, p53 and actin. 
 
Figure 2.9. A model for the inhibitory effects MdmX exerts on p53.  
MdmX inhibits p53 both directly, through binding to its trans-activation domain 
and preventing it from recruiting transcriptional co-activators and indirectly, 
through promoting the activation of the p53 inhibitors Mdm2 and Wip1. 
Figure 2.S1. Over-expressed myc-MdmX does not enhance the expression 
of Mdm2 following NCS treatment. MCF7 cells (A) and U2OS cells (B) were 
transfected with increasing amounts of myc MdmXencoding plasmid, balanced 
with empty vector to a total of 2 g per transfection for 24 hr. Cells were then 
treated with NCS for 4 hr. bar graphs show the levels of p21 , Mdm2 and MdmX 
mRNAs as measured by qRT-PCR as indicated. Bottom panels chow 
Immunoblot analysis with antibodies against Mdm2, MdmX, p53, p21 and actin. 
 
Figure 2.S2. The requirement of MdmX for full Mdm2 mRNA levels after 
NCS treatment does not depend on the p53: Mdm2 interaction. MCF7 cells 
were transfected with control (Luc) or MdmX siRNA (50 nM) for 48 hr prior to 
treatment with NCS (300 ng/mL) for 4 hr. In the experiment with Nutlin + NCS 
(Nut + NCS) Nutlin-3 (10 M) was added for 12 hr at 36 hr after siRNA 
transfection followed by co-treatment with Nutlin-3 (10 M) and NCS (300 ng/mL) 
together for 4 hr. Nutlin-3 alone (10 M) was administered for total of 16 hr in two 
applications, first for 12 hr followed by an additional 4 hr, 36 hr after transfection 
with siRNA. A. Panels show levels of Mdm2 (left) and p21 (right) mRNAs in the 
different conditions as measured by qRT-PCR. B. Immunoblot analysis using 
antibodies against MdmX, Mdm2, p53, p21 and actin as indicated. C. Co-
immunoprecipitation experiment was performed with lysates prepared from 
MCF7 cells that were transfected with control (Luc) or MdmX siRNA (50 nM) for 
48 hr followed by NCS treatment (300 ng/mL) for 90 min. p53 was 
immunoprecipitated with monoclonal antibody 1801. Input and 
immunoprecipitated (p53 IP) samples were analyzed by immunoblotting using 
antibodies against Mdm2, MdmX, p53 and actin. 
 
Figure 2.S3. Dynabeads conjugated to Mdm2 biotinylated probes are not 
saturated for p53 binding. Lysates were prepared from MCF7 cells as 
described in Figure 5. Different amount of lysates were added (1, 2 and 4 g total 
protein) and run alongside Input material (3%) and post DNA pull down samples 
(3%). Increasing amounts of p53 were bound to the biotinylated DNA as a 
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ABSTRACT 
Mdm2 and MdmX negatively regulate the tumor suppressor p53. Additionally, 
they each play p53-independent roles as well as exert positive regulation of p53 
activity. PCNA is a DNA sliding clamp that is required for DNA replication and 
coordinates multiple aspects of DNA biology. It is reported to be both a direct 
activation target of p53, as well as an indirect repression target. We report here 
that in wild type p53-harboring MCF7 cells MdmX and Mdm2 down-regulation 
leads to reduced PCNA mRNA levels and activation of the p53 target gene p21. 
In cells treated with siRNA targeting MdmX, although RNA polymerase II levels 
at the PCNA promoter are reduced, p53 recruitment is increased, suggesting a 
possible p53-independent effect. In p53 null H1299 cells Mdm2 but not MdmX 
siRNA leads to a reduction in PCNA levels, while not activating p21. Interestingly, 
p53 over-expression does not render the cells responsive to MdmX siRNA. Cell 
cycle analysis shows that in both cell lines PCNA reduction in response to MdmX 
or Mdm2 siRNA is accompanied by cell cycle arrest at the G1/S transition. Thus, 
we show that in both a p53 positive and a p53 null cell line knock down of the 
p53 negative regulators leads to cell cycle arrest and reduced PCNA levels.  
INTRODUCTION 
The tumor suppressor p53 is mutated in over 50% of cancers, and its 
pathway is deregulated in other ways such as amplification or over-expression of 
p53’s negative regulators Mdm2 and MdmX in the remaining group (Manfredi, 
2010; Momand et al., 1998; Oliner et al., 1992). Mdm2 and MdmX are 
homologous proteins that inhibit p53 trans-activation activity by interacting with 
its N-terminal trans activation domain (TAD) (Oliner et al., 1993; Shvarts et al., 
1996; Stad et al., 2000). Although both Mdm2 and MdmX possess highly similar 
C-terminal RING domains, only Mdm2 is capable of ubiquitinating p53 and 
targeting it for degradation by the proteasome (Haupt et al., 1997; Honda et al., 
1997; Stad et al., 2000).  
It was initially assumed that Mdm2 and MdmX are nondiscriminatory 
inhibitors of p53 transactivation functions. Multiple lines of evidence now suggest 
that Mdm2 and MdmX affect target gene selectivity by p53 in a cell and tissue 
specific manner. This difference in function between Mdm2 and MdmX might be 
explained by structural analysis of both proteins bound to a p53 N-terminal TAD 
peptide showing that the p53 binding pockets are not identical, with two amino 
acids partially blocking the hydrophobic pocket in MdmX (Popowicz et al., 2008; 
Popowicz et al., 2007). Furthermore, while Mdm2 strongly inhibits p53:DNA 
interactions (Cross et al., 2011; Poyurovsky et al., 2010; Zauberman et al., 
1993), MdmX does so at a much lesser extent (Cross et al., 2011). In a recent 
study, MdmX was shown to protect p53 from ubiquitin-independent proteasomal 
degradation following DNA damage by affecting its conformation, while Mdm2 
cannot perform this function (Di Conza et al., 2012), demonstrating differential 
effects upon p53 interaction. Moreover, Mdm2 and MdmX perform non-
redundant functions during mouse development, as deletion of either protein is 
embryonic lethal and can be rescued by co-deletion of p53 (Jones et al., 1995; 
Migliorini et al., 2002; Montes de Oca Luna et al., 1995; Parant et al., 2001). 
PCNA is a homotrimeric DNA sliding clamp that coordinates and affects 
multiple steps in DNA replication and repair, including increasing the processivity 
of the replicative polymerases, preventing DNA reduplication through 
coordinating Cdt1 degradation, promoting both error prone trans lesion synthesis 
as well as error free repair of DNA damage (Moldovan et al., 2007). PCNA 
interacts with a large array of partner proteins (Naryzhny, 2008), primarily 
through their PCNA interacting protein (PIP) motif (Xu et al., 2001), and these 
interactions are further regulated by PCNA post-translational modifications. 
Theoretically, each PCNA trimer could interact with three different partners 
(Maga and Hubscher, 2003; Stoimenov and Helleday, 2009).  
PCNA is linked to the p53 pathway in multiple ways. p53, Mdm2 (Banks et 
al., 2006) and p21 (Waga et al., 1994; Warbrick et al., 1995) contain a PIP motif 
and were shown to interact with PCNA. While the importance and implications of 
Mdm2 and p53’s interactions with PCNA are not very well understood, p21’s 
effects on PCNA are well studied and have been recently reviewed (Livneh, 
2006; Prives and Gottifredi, 2008; Soria and Gottifredi, 2010). Moreover, p53 was 
shown to both directly activate the PCNA gene (Shan et al., 2003; Shivakumar et 
al., 1995; Xu and Morris, 1999), and indirectly repress its activation (Mercer et 
al., 1991; Yamaguchi et al., 1994). 
We are interested in the differential effects of Mdm2 and MdmX 
knockdown on gene expression and have recently demonstrated that MdmX is 
required for p53 interaction with the Mdm2 promoter and for full activation of 
Mdm2 following cellular stress (Biderman et al., 2012). In this study we examine 
the expression of the PCNA gene in response to MdmX and Mdm2 ablation.  
In MCF7 cells, which harbor wild-type p53, PCNA mRNA was reduced in 
response to both MdmX and Mdm2 down-regulation with siRNA. In fact, basal 
PCNA mRNA levels do not depend on p53 in MCF7 cells, as p53 ablation did not 
reduce PCNA levels. Remarkably, in a p53 null cell line (H1299), we saw 
reduced PCNA mRNA in response to Mdm2 but not MdmX siRNA treatment. 
Moreover, upon MdmX ablation in MCF7 cells, PCNA mRNA is reduced, but p53 
binding to the PCNA promoter is actually increased. RNA polymerase II-promoter 
binding, on the other hand, is lowered following MdmX ablation. PCNA 
transcription is also regulated by the cell cycle (Almendral et al., 1987; Bolton et 
al., 1992; Gazitt et al., 1993; Kurki et al., 1986; Stewart and Dell'Orco, 1992). 
Indeed, we found a correlation between PCNA mRNA levels and cell cycle 
progression. Thus, our data suggest that ablation of MdmX or Mdm2 induces cell 
cycle arrest and leads to a reduction in PCNA mRNA levels. 
MATERIALS AND METHODS 
Cell culture. MCF7 and H1299 cells were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum. Drug 
treatments were as follows:  neocarzinostatin (300 ng/mL, Kayaku Co., Tokyo, 
Japan) was added for 4 hr or as indicated, while 5-fluorouracil (500 nM, Sigma-
Aldrich, St Louis, MO, USA), actinomycin D (4 nM, Calbiochem, San Diego, CA, 
USA), doxorubicin (100 nM, Sigma-Aldrich, St Louis, MO, USA), daunorubicin 
(0.22 M, Sigma-Aldrich, St Louis, MO, USA) and camptothecin (300 nM, Sigma-
Aldrich, St Louis, MO, USA) were administered for 8 hr. Cell synchronization by 
double thymidine block was performed as follows. Thymidine (2 mM, Sigma-
Aldrich, St Louis, MO, USA) was added to cells for 16 hr, washed off and 
replaced with fresh media for 9 hr, followed by another addition of thymidine for 
additional 16 hr incubation. The cells were then washed once and fresh media 
added. Cells were collected every two hr.  
 
Transfection. siRNA duplexes were obtained from Qiagen (Valencia, CA, 
USA) and Invitrogen (Carlsbad, CA, USA) and transfected into cells with 
DharmaFECT 1 reagent (Dharmacon, Thermo Fisher Scientific, Lafayette, CO, 
USA) for 48 hr. siRNA sequences were as follows: siLuc (Urist et al., 2004), 
siMdmX (Chen et al., 2005), siMdm2 siRNA #1 as described in (Zhu et al., 2009), 
sip53_1 sense: AACTACTTCCTGAAAACAACG, sip53_2 sense: 
AAAGACCTATGGAAACTACTT. 
Quantitative reverse transcription polymerase chain reaction 
analysis (qRT-PCR). RNA was isolated from cultured cells using the QIAGEN 
RNeasy Mini kit and reverse transcribed into cDNA with QuantiTect Reverse 
Transcription kit (QIAGEN, Valencia, CA, USA). PCR was performed with either 
Prism 7300 or StepOnePlus Real-Time PCR system using Power SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Relative mRNA 
levels were calculated using the Ct method, normalized first to the levels of 
control RPL32 mRNA, and then to the levels of the plotted mRNA in untreated 
siLuc control sample. Primer sequences are available upon request. Graphs are 
representative of multiple independent experiments, with error bars representing 
technical PCR replicates. 
 
Immunoblot analysis (Western blot). Whole cell lysates were analyzed 
by standard immunoblotting procedure as previously published (Biderman et al., 
2012; Urist et al., 2004). Commercially obtained antibodies used in this study 
were MdmX A300-287A (Bethyl laboratories, Montgomery, TX, USA); p21 (C-19) 
sc-397, Pol II (N-20) sc-899 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
and PCNA (Ab-1) NA03 (Calbiochem, San Diego, CA, USA). The following 
mouse monoclonal antibodies were used as hybridoma supernatants: p53 (DO-1, 
1801) and Mdm2 (3G5, 5B10, 4B11). 
Chromatin Immunoprecipitation (ChIP). ChIP assay was performed as 
previously published (Biderman et al., 2012) using antibodies against Pol II (N-
20) sc-899 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p53 DO1/1801 
hybridoma mix or MdmX A300-287A (Bethyl laboratories, Montgomery, TX, 
USA). 
 
Cell cycle analysis by flow cytometry. Cells pellets were washed with 
phosphate buffered saline (PBS) and fixed/permeabilized with 50% ice-cold 
ethanol. Pellets were washed with PBS and resuspended in 62.5 μg/ml 
propidium iodide and 50 μg/ml ribonuclease A. Samples were analyzed using 
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA). ModFit LT Version 
3.0 program (Verity Software House, Topsham, ME, USA) was used to 
determine the percent of cells in each stage of the cell cycle. 
 
RESULTS 
PCNA mRNA levels are reduced following siMdmX treatment. In order 
to study the effects of MdmX ablation on p53 target gene expression MCF7 
breast cancer cells were transfected with control siRNA (Luc) or siRNA directed 
at MdmX and either left untreated or treated with the radiomimetic drug 
neocarzinostatin (NCS) for 2 and 4 hr (Fig. 3.1A and 3.1B). PCNA mRNA, unlike 
other tested p53 targets, was reduced following treatment with siMdmX both in 
untreated cells (0 hr NCS) as well as following NCS treatment (Fig. 3.1A). As 
reported in our previous study (Biderman et al., 2012), Mdm2 and Wip1 mRNA 
levels were reduced in response to MdmX siRNA treatment only following 
treatment with NCS, while p21, 14-3-3 , cyclin G1 (CCNG1), Bax, Pig3 and 
Noxa did not require MdmX for their expression in either condition (Fig. 3.1A). 
Immunoblot analysis showed MdmX knockdown was efficient (Fig 3.1B). By 4 hr 
NCS treatment only a modest induction of PCNA mRNA was observed (Fig. 
3.1A). We therefore extended the treatment with NCS and examined mRNA 
levels every 2 hr up to 8 hr NCS treatment (Fig. 3.1C). PCNA levels in siLuc-
treated samples peaked at 4 hr post NCS, but still, the induction of PCNA mRNA 
following NCS is very poor (from 1 to 1.26 relative expression), and was followed 
by a reduction to 0.65 of initial levels by 8 hr NCS (Fig. 3.1C). MdmX siRNA 
reduced the levels of PCNA mRNA in both untreated as well as all treated 
samples. Mdm2 and p21 mRNA induction peaked at 4 hr NCS treatment, and 
peak Mdm2 induction was compromised by the siMdmX treatment as previously 
shown (Biderman et al., 2012) (Fig. 3.1C). Immunoblot analysis showed the 
MdmX knockdown was efficient (Fig. 3.1D).  
 
PCNA expression is dependent on MdmX regardless of the stress 
applied. We next examined whether PCNA levels are induced in response to 
other cellular stressors, and how MdmX siRNA affects those levels. MCF7 cells 
were first treated with control siRNA (Luc) or MdmX siRNA, and then treated with 
a variety of different cellular stressors: NCS, the thymidylate synthase inhibitor 5-
fluorouracil (5FU), the RNA and DNA synthesis inhibitor actinomycin D (ActD), 
topoisomerase II inhibitors doxorubicin (Doxo) and daunorubicin (Dauno), or the 
topoisomerase I inhibitor camptothecin (CPT) (Fig. 3.2). PCNA mRNA levels 
following NCS application were comparable to the levels following 5FU and CPT 
treatments, all around 1.7 fold induction, which was the maximum induction 
detected (Fig. 3.2A), suggesting PCNA is a rather weak target of p53 under 
these conditions. In each case, knockdown of MdmX compromised PCNA mRNA 
levels, reducing them down to 0.4-0.5 relative levels compared the levels in 
untreated siLuc sample. Thus, PCNA is unique among p53 target genes in that 
its basal levels in un-stressed cells require adequate expression of MdmX. 
 
MdmX and Mdm2 siRNA reduce basal PCNA levels in MCF7 cells, but 
sip53 does not. Since the induction of PCNA following a variety of cellular 
stressors was so weak, we tested whether PCNA mRNA levels are regulated by 
p53 in MCF7 cells. Additionally, we tested the effects of ablating the MdmX 
homolog, Mdm2, with siRNA on PCNA levels. MCF7 cells were transfected with 
control siRNA (Luc) or two different siRNA sequences directed at p53 separately 
or together, or siRNA directed at MdmX or Mdm2 (Fig. 3.3). p53 knockdown with 
each siRNA separately or the two together was efficient (Fig. 3.3A and 3.3B 
lanes 2-4). Accordingly, both p21 and Mdm2 mRNA and protein levels were 
reduced following p53 ablation (Fig. 3.3A and 3.3B). PCNA levels, however, were 
unaffected by the p53 siRNA treatment. siRNA directed at MdmX or Mdm2, on 
the other hand, lead to a marked reduction in PCNA levels (Fig. 3.3A). We noted 
that Mdm2 knockdown leads to a reduction in MdmX, and thus may function 
through MdmX (Fig. 3.3A). However, since MdmX protein levels were unaffected 
by Mdm2 siRNA (Fig. 3.3B), we conclude that both MdmX and Mdm2 are 
required for maintaining normal PCNA mRNA levels in MCF7. There may be two 
possible explanations for our observation that p53 siRNA did not affect PCNA 
mRNA levels: either p53 does not regulate basal PCNA levels, or perhaps p53 
knockdown in our hands was insufficient to affect PCNA levels. We therefore 
proceeded to test the regulation of PCNA in cells lacking p53. 
 
PCNA mRNA levels depend on Mdm2 but not MdmX in the p53 
deficient H1299 cell line. p53 null lung cancer cell line H1299 was transfected 
with control siRNA (Luc) or siRNA directed at MdmX or Mdm2, and either left 
untreated or treated with NCS. Surprisingly, PCNA mRNA levels were reduced 
following Mdm2 but not MdmX siRNA, in both untreated as well as NCS-treated 
cells (Fig. 3.4A). Thus, there is a discrepancy between the way PCNA is 
regulated in MCF7 compared to H1299 cells. In MCF7 cells both MdmX and 
Mdm2 siRNA reduced PCNA mRNA, while in H1299 it was only siMdm2 that 
affected PCNA mRNA levels. These differences may be due to the fact that 
MCF7 contain p53 while H1299 do not. Alternatively, there may be other factors 
determining the dependence on MdmX.  
 We therefore examined the effects of siMdmX and siMdm2 in the H24-p53 
cell line, a derivative of H1299 cells that were engineered to express p53 upon 
removal of tetracycline from the growth media (Chen et al., 1996). A titration of 
decreasing amounts of tetracycline led to gradual increase in p53 levels and a 
concomitant increase in p21 protein levels (Fig. 3.4D), suggesting p53 was 
transcriptionally active. Moreover, Mdm2 mRNA levels increased as a function of 
p53 induction (Fig. 3.4C). In cells containing 40 ng/mL tetracyclin, turning off p53 
expression, MdmX siRNA had a mild reducing effect on PCNA levels (30% 
reduction, from 1 to 0.7 relative expression in siLuc and siMdmX-treated cells 
respectively), while Mdm2 siRNA led to a 70% reduction in PCNA levels. p53 
induction did not render PCNA mRNA levels more dependent on MdmX (Fig. 
3.4C). Thus, the difference between MCF7 and H1299 cells in PCNA mRNA’s 
responsiveness to siMdmX does not seem to be due to the p53 status. 
  
Recruitment of RNA polymerase II to the PCNA promoter does not 
correlate with p53 promoter binding. Our data so far suggest that PCNA may 
not be regulated by p53. To further study this, we examined whether p53 
recruitment to the PCNA promoter is reduced following MdmX siRNA. MCF7 
cells were transfected with siLuc or siMdmX, and subjected to ChIP protocol. 
Quantitative real time PCR was used to determine the amount of DNA bound, 
amplifying the p53 binding site regions from the PCNA promoter, p21 5’ response 
element and a negative control region. MdmX siRNA resulted in an increase in 
p53 interaction at both the PCNA and p21 promoters (Fig. 3.5A). Our previous 
results showed that p21 mRNA increases following MdmX siRNA (Fig. 3.1 and 
3.3), a result that is in agreement with increased p53 recruitment to the p21 
promoter activating its expression. PCNA mRNA, on the other hand, decreases 
upon MdmX ablation (Fig. 3.1, 3.2 and 3.3). We considered possible hypotheses 
trying to explain the discrepancy between increasing p53 interaction with PCNA 
promoter and the lower PCNA mRNA following MdmX siRNA treatment. p53 
activates its target genes in a variety of ways. Some promoters are activated at 
levels of recruitment of basal transcription machinery and the formation of pre-
initiation complex, while other genes have polymerase poised there, and 
elongation is directed by p53 (Beckerman and Prives, 2010; Espinosa, 2008; 
Espinosa et al., 2003). To examine post DNA binding steps in p53-mediated 
gene regulation, we examined whether RNA polymerase II (Pol II) is recruited to 
the PCNA promoter following MdmX knockdown. ChIP using antibodies directed 
against RPB1, the large subunit of Pol II, showed that Pol II levels at the PCNA 
promoter decrease following MdmX siRNA, while at the p21 promoter there is an 
increase in chromatin-bound Pol II (Fig. 3.5A). Our interpretation of the data is 
that basal PCNA levels are probably not regulated by p53. An alternative 
explanation, that p53 is a transcriptional repressor of PCNA under these 
conditions, is unlikely based on the observation that knocking down p53 did not 
increase PCNA levels (Fig. 3.3A), as would be expected in such case.  
A reduction in PCNA mRNA levels following MdmX or Mdm2 ablation 
correlates with cell cycle arrest. In addition to being regulated by p53 in 
response to DNA damage, PCNA expression is also regulated by the cell cycle, 
with high levels in the synthesis (S) phase and low levels throughout the rest of 
the cycle (Almendral et al., 1987; Bolton et al., 1992; Gazitt et al., 1993; Kurki et 
al., 1986; Stewart and Dell'Orco, 1992). We therefore hypothesized that the 
change in PCNA mRNA levels may be a secondary effect to cell cycle arrest in 
response to treatment with MdmX or Mdm2 siRNA. MCF7 and H1299 cells were 
transfected with control, MdmX or Mdm2 siRNA. Cells were then harvested and 
analyzed with respect to cell cycle profile (Fig. 3.6A and 3.6E), plotting percent 
cells in S phase (Fig. 3.6B and 3.6F), PCNA mRNA levels (Fig. 3.6C and 3.6G), 
and Mdm2 and MdmX mRNA levels to control for their ablation (Fig. 3.6D and 
3.6H). Upon treatment of MCF7 cells with both siRNA directed at MdmX and 
Mdm2 the cell cycle was arrested, with an increase in percentage of cells in G1 
phase (51.03%, 74.41%, 68.45% in siLuc, siMdmX and siMdm2-treated cells 
respectively) and a decrease of cells in S phase (40.33%, 19.32%, 25.83% in 
siLuc, siMdmX and siMdm2-treated cells respectively) (Fig. 3.6A and 3.6B). As 
seen before, PCNA mRNA levels were lower in cells treated with siMdmX and 
siMdm2 compared to control siLuc siRNA (Fig. 3.6C). H1299 cells, unlike MCF7, 
arrest only in response to Mdm2 siRNA with an increase in G1 (51.47%, 57.40%, 
74.57% in siLuc, siMdmX and siMdm2-treated cells respectively) and decrease in 
S phase (37.62%, 32.90%, 17.28% in siLuc, siMdmX and siMdm2-treated cells 
respectively). PCNA levels, again, were also reduced just in response to Mdm2 
siRNA and not to MdmX ablation. Thus, the levels of PCNA mRNA correlate with 
the cell cycle response to the specific siRNA. When the cells arrest (MCF7 in 
response to both siMdmX and siMdm2, and H1299 in response to siMdm2), 
PCNA levels decrease. When the cells do not arrest (MCF7 in response to 
control siLuc and H1299 in response to siLuc as well as siMdmX), PCNA mRNA 
levels remain unchanged (Fig. 3.6). These observations are in line with our 
hypothesis that the changes in PCNA mRNA levels upon MdmX or Mdm2 
knockdown are secondary effects of alterations in cell cycle progression. 
 In order to further support our hypothesis we tested whether in MCF7 and 
H1299 cell lines PCNA mRNA levels are regulated as a function of cell cycle 
progression. MCF7 and H1299 cells were synchronized at the G1/S transition 
using the double thymidine block, and collected every two hr following removal of 
thymidine from the growth media. DMSO was used as control for asynchronous 
cells (Fig. 3.7). Cell cycle analysis by flow cytometry showed that both MCF7 and 
H1299 cells synchronized well, with all cells arresting at the G/S transition. 
Release from thymidine block worked as well, and most cells progressed to S 
phase by 2 hr after washing off the thymidine and into G2 by 4-6 hr (Fig. 3.6A 
and 3.6C). PCNA mRNA levels tracked the cell cycle progression, with highest 
levels in cells arrested at the G1/S (0 he post release) and as the cells entered S 
phase (2 hr post release). When the cells progressed to G2/M phase PCNA 
mRNA decreased, reaching lowest levels at 8 hr, and increasing as more cells 
progressed through G1 at 10 and 12 hr (Fig. 3.6B and 3.6D). Thus, in agreement 
with published results (Almendral et al., 1987; Bolton et al., 1992; Gazitt et al., 
1993; Kurki et al., 1986; Stewart and Dell'Orco, 1992) PCNA mRNA regulation by 
cell cycle progression can be detected in our system. 
 
DISCUSSION 
We show here that down-regulation of the p53 inhibitors Mdm2 and MdmX 
leads to activation of p21, cell cycle arrest and PCNA mRNA reduction in the p53 
wild-type cell line MCF7, while in the p53 null cell line H1299 ablation of Mdm2 
but not MdmX caused this phenotype, though in this case p21 is not activated. 
Multiple studies have identified PCNA as a p53 target gene, showing that 
p53 interacts with and activates the PCNA promoter in response to stress (Shan 
et al., 2003; Shivakumar et al., 1995; Xu and Morris, 1999). Conversely, p53 
over-expression or activation was also shown to correlate with down-regulation of 
PCNA mRNA levels (Mercer et al., 1991; Yamaguchi et al., 1994). An analysis of 
p53’s effects on PCNA promoter reporter gene activity in a variety of cell lines 
showed that while over-expression of p53 leads to repression of PCNA in most 
tested cell lines, including human SAOS2, hamster CHO, monkey CV1, and 
mouse L929 cells, it actually activated it in HeLa cells. Deletion analysis revealed 
that there are two regions in the PCNA promoter, one positively and one 
negatively affecting transcription upon p53 activation (Jackson et al., 1994). In a 
more physiological context, it was shown that p53 is expressed during mouse 
kidney development, correlating with cell terminal differentiation and reduced 
PCNA levels. Moreover, in the kidneys of p53 null mice, PCNA expression 
pattern is disrupted. Importantly, while p53 represses PCNA reporter gene in 
cells, deletion of the p53 response element enhanced this inhibition, suggesting 
an indirect role for p53 in PCNA inhibition (Saifudeen et al., 2002). 
An explanation of the opposite effects of p53 activation on PCNA gene 
expression comes from the initial observation that the PCNA gene is regulated by 
the cell cycle, with protein and mRNA peaking at the G1/S transition and early S 
phase, and decreasing thereafter (Almendral et al., 1987; Bolton et al., 1992; 
Gazitt et al., 1993; Kurki et al., 1986; Stewart and Dell'Orco, 1992). 
Mechanistically, the PCNA promoter is regulated by cell cycle progression 
through the E2F transcription factors (Li et al., 2003; Tommasi and Pfeifer, 1999) 
in response to mitogenic stimuli. The CDK-inhibitor p21, a target of p53, 
mediates cell cycle arrest. Interestingly, p21 inhibits E2F-mediated transcription 
through multiple ways, both indirectly through the inhibition of CDKs and by 
directly interacting with E2F (Dotto, 2000). p21 therefore mediates negative 
effects of transcription in response to p53 activation (Lohr et al., 2003). Thus, p53 
may repress the transcription of PCNA through the activation of p21. 
In addition to being regulated by the cell cycle, PCNA also controls the cell 
cycle. PCNA down-regulation by siRNA or shRNA leads to inhibition of DNA 
synthesis and cell cycle arrest at the G1/S transition (Hao et al., 2008; Jaskulski 
et al., 1988; Liu et al., 1989). There seems to be a threshold of PCNA needed for 
progression into S phase, as a 40% decrease in PCNA protein levels was 
sufficient to cause G1 arrest (Jaskulski et al., 1988). Thus, PCNA is both 
regulated by the cell cycle and is regulating cell cycle progression. We cannot 
firmly answer at this point whether in our work Mdm2 or MdmX siRNA’s primary 
effect is to arrest the cell cycle, leading to lower PCNA levels, or, alternatively, 
whether Mdm2 or MdmX siRNA lead to PCNA down-regulation and thus halting 
cell cycle progression. In MCF7 cells treated with siMdm2 or siMdmX siRNA p21 
mRNA and protein levels increase as PCNA mRNA decreases. However, since 
there was no detectable reduction of PCNA protein levels, it is likely that the 
reduction in PCNA mRNA is secondary to the cell cycle arrest caused by 
induction of p21. In H1299, on the other hand, we did observe a reduction in 
PCNA protein upon Mdm2 siRNA treatment while not observing an increase in 
p21, suggesting that in this cell line cell cycle arrest is p21-independent, and may 
be either the cause of the lower PCNA or the result of such reduction. MdmX and 
Mdm2 siRNA treatment in H1299 was previously shown to stabilize the p21 
protein and arrest the cells in G1 (Jin et al., 2003; Jin et al., 2008). In our hands, 
however, we did not observe this increase in p21 with either siRNA, nor did we 
observe cell cycle arrest when the cells were treated with siMdmX. Further 
analysis is needed for determining which mechanism is acting in MCF7 and in 
H1299 cells.  
PCNA is regulated both at the transcriptional and post-transcriptional 
levels, with intronic sequences appearing to play a role in post-transcriptional 
control of PCNA gene expression (Chang et al., 1990; Sell et al., 1992). PCNA 
gene expression is not regulated by promoter methylation (Liu et al., 1993). If 
indeed PCNA down-regulation is a primary effect of Mdm2 knockdown in H1299 
cells, how Mdm2 positively regulates PCNA mRNA levels in p53 null cells is an 
interesting question. With PCNA being regulated at multiple levels, many 
possibilities need to be tested. For example, Mdm2 may promote E2F-mediated 
expression of PCNA, or Mdm2 may be regulating PCNA mRNA stability. 
Conversely, if Mdm2 leads primarily to cell cycle arrest, it is interesting to 
discover the p53-independent mechanism for achieving this. 
PCNA is required for cell division, and as such, its levels are elevated in 
many cancers. In fact, it is often used as a marker for replicating tumor cells, and 
in some cancers serves as a prognostic marker (Caputi et al., 1998; del Giglio et 
al., 1992). p53 or Mdm2 are deregulated in virtually all cancers, and a search for 
Mdm2 inhibitors that will activate p53 is well underway (Vassilev, 2007). In this 
work we show that in MCF7 cells, which express wild type p53, lowering the 
expression of either MdmX or Mdm2 leads to increased p21 expression, cell 
cycle arrest and reduced PCNA mRNA levels. Interestingly, in the p53 null 
H1299 cell line Mdm2 knockdown leads to cell cycle arrest without up-regulation 
of p21, and a concomitant reduction in both PCNA mRNA and protein. Figuring 
out which aspect of the Mdm2 protein in required for this activity may lead to 
development of inhibitors that arrest the cell cycle even in tumor cells lacking 
p53. 
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FIGURE LEGENDS 
 
Figure 3.1. PCNA mRNA levels are reduced following siMdmX treatment.   
MCF7 cells were transfected with 50 nM control (Luc) or MdmX siRNA and either 
untreated (0) or treated with NCS (300 ng/mL) for 2 and 4 hr. A. mRNA levels of 
p53 target genes were quantitated by qRT-PCR and averaged over three 
experiments. B. Immunoblot analysis of a representative experiment with 
antibodies against MdmX, Mdm2, p53 and actin.  C. MCF7 cells were transfected 
with MdmX siRNA (50 nM) for 48 hr followed by treatment with NCS (300 ng/mL) 
for the indicated times. PCNA, Mdm2 and p21 mRNA levels were determined 
using qRT-PCR. D. Immunoblot analysis of experiment shown in C using 
antibodies against Mdm2, MdmX, p53 and actin. 
 
Figure 3.2. PCNA expression is dependent on MdmX regardless of the 
stress applied. A. MCF7 cells were transfected with control or MdmX siRNA for 
48 ours followed by no treatment (NT), treatment for 4 hr with NCS (300 ng/mL), 
or treatment for 8 hr with 5-fluorouracil (5FU, 500 nM), actinomycin D (ActD, 4 
nM), doxorubicin (Doxo, 100 nM), daunorubicin (Dauno, 0.22 M) or 
camptothecin (CPT, 300 nM). PCNA mRNA levels were quantified by qRT-PCR 
analysis. B.  Immunoblot of the experiment in A was performed using antibodies 
against MdmX, p53, Mdm2 and actin. 
Figure 3.3. MdmX and Mdm2 siRNA reduce basal PCNA levels in MCF7 
cells, but sip53 does not. MCF7 cells were transfected with control (Luc) 
siRNA, siRNA targeting p53 with two different sequences: sip53_1 or sip53_2 or 
sip53_1 and sip53_2 together, siMdmX or siMdm2 for 48 hr (50nM each, 
balanced with 50nM siLuc all samples except sip53_1+sip53_2). A. PCNA, p21, 
p53, MdmX and Mdm2 mRNA levels were determined by qRT-PCR. B. 
Immunoblot of the experiment in A was performed using antibodies against 
MdmX, Mdm2, p53, PCNA, p21 and actin.  
 
Figure 3.4. PCNA mRNA levels depend on Mdm2 but not MdmX in the p53 
deficient H1299 cell line. H1299 cells were transfected with control or MdmX 
siRNA for 48 ours followed by no treatment (NT), treatment for 4 hr with NCS 
(300 ng/mL) (A and B). A. PCNA, MdmX, p21 and Mdm2 mRNA levels were 
determined by qRT-PCR. B. Immunoblot of the experiment in A was performed 
using antibodies against MdmX, Mdm2, PCNA, p21 and actin. C. H24-p53 
tetracycline-inducible cells were grown in the presence of tetracycline, 
transfected with siLuc, siMdmX or siMdm2. 24 hr later the cells were washed and 
tetracycline was added at the stated concentrations (40 ng/mL p53 off to 0 ng/mL 
p53 on). PCNA, MdmX and Mdm2 mRNA levels were quantitated by qRT-PCR. 
D. Immunoblot of the experiment in C was performed using antibodies against 
p53, PCNA, p21 and actin. 
Figure 3.5. Recruitment of RNA polymerase II to the PCNA promoter does 
not correlate with p53 promoter binding. MCF7 cells were transfected with 
Luc control siRNA or MdmX siRNA for 48 hr. ChIP was performed with 
antibodies against the large subunit of RNA polymerase (pol II) MdmX, p53 or no 
antibody as control (no Ab) as indicated. A. ChIP-enriched DNA was quantitated 
by Real-Time PCR with primers amplifying the p53 REs from the PCNA or p21 
promoters, or a negative control region (control). B. Immunoblot analysis of input 
material using antibodies against MdmX, p53, pol II, p21 and actin. 
 
Figure 3.6. A reduction in PCNA mRNA levels following MdmX or Mdm2 
ablation correlates with cell cycle arrest. MCF7 (A-D) and H1299 (E-H) cells 
were transfected with control or MdmX siRNA for 48. Cells were then analyzed 
by FACS for evaluating cell cycle distribution (A and E) and percent cells in S 
phase plotted (B and F), qRT-PCR was used to quantitate mRNA levels of PCNA 
(C and G), Mdm2 and MdmX (D and H).  
 
Figure 3.7. PCNA mRNA levels are high in G1/S and decrease thereafter. 
MCF7 and H1299 cells were synchronized by the double thymidine block method 
as described in methods. Cell cycle profile was analyzed by FACS (A and C).  










































































































PERSPECTIVES AND FUTURE DIRECTIONS 
 
In this work we have reviewed the emerging roles of Mdm2 and MdmX in 
the regulation of gene expression. Although these proteins were initially assumed 
solely to inhibit all activities of p53, newer evidence suggests that Mdm2 and 
MdmX have a variety of functions in cells, including affecting target gene 
selectivity by p53 as well as exerting p53-independent effects on transcription 
factors. Thus, Mdm2 and MdmX form links between the p53 pathway and other 
signaling pathways, such as the pRb pathway through affecting E2F1 (Polager 
and Ginsberg, 2009), and the TGF  signaling through influencing the activity of 
Smad proteins (Kadakia et al., 2002; Sun et al., 1998; Yam et al., 1999). 
Moreover, Mdm2 affects mRNA stability and translatability and can also function 
as a transcription co-factor itself. 
 In chapter two we examined a role for MdmX in the activation of the p53 
target gene Mdm2. We showed that MdmX is required for p53 interaction with 
chromatin, but not with purified DNA in vitro. And, accordingly, that MdmX 
interacts with chromatin at the Mdm2 promoter locus, but not with purified DNA 
spanning that region in vitro.  
In a small-scale analysis of p53 target genes we identified the two p53 
target genes involved in forming negative feedback loops, Mdm2 and Wip1 
requiring MdmX for their full expression following DNA damage. It would be 
interesting to examine global transcriptional responses to MdmX siRNA using 
microarray analysis. There is one report describing such an experiment 
(Heminger et al., 2009). This study, however, focused on genes that are 
commonly affected by Mdm2 and MdmX knockdown. Analysis of the genes that 
are differentially affected following either Mdm2 or MdmX down regulation basally 
as well as following DNA damage would help us uncover differences between the 
two Mdm protein functions.  
We showed that MdmX interacts preferentially with the Mdm2 promoter 
locus when compared to the p21 locus. Various studies have reported Mdm2 
interacting with DNA (Arva et al., 2005; Jin et al., 2004; Minsky and Oren, 2004; 
Ohkubo et al., 2006; Tang et al., 2008; White et al., 2006), while just a single 
report of over-expressed MdmX interacting with chromatin exists (Tang et al., 
2008). A global ChIP experiment, in which DNA recovered from the 
immunoprecipitated protein is identified by either deep sequencing or microarray 
hybridization will enable us to asses whether the genes whose expression is 
affected by the Mdm2 or MdmX siRNA treatment are affected due to the Mdm 
protein directly functioning on chromatin, or indirectly functioning, for example, 
through other transcription factors, or, possibly, affecting mRNA stability.  
 What determines the localization of MdmX on DNA is not clear. MdmX 
interacts with Mdm2 promoter DNA in the context of the cell, but not in vitro, 
suggesting chromatin structure or modifications may be involved. An analysis of 
the sequences identified by the global ChIP experiment suggested above may 
help identify regions or sequences preferentially bound by MdmX. The Mdm2 
promoter is relatively nucleosome free in a mouse embryonic fibroblast cell line 
(Xiao et al., 1998). To assess whether MdmX preferentially binds nucleosome 
free regions, an analysis of nucleosome occupancy can be performed, and 
compared to regions bound by MdmX. ChIP using antibodies against specific 
chromatin modifications may reveal MdmX’s requirements for chromatin 
interaction. 
 We started examining whether MdmX’s interaction with chromatin is p53-
dependent. p53 down regulation in MCF7 cells with siRNA affected p53 
association with the Mdm2 gene promoter (Fig. 4.1A), but not the association of 
MdmX (Fig. 4.1B). These data indicate that MdmX recruitment to the Mdm2 
promoter is p53 independent. Whether the DNA interaction of MdmX is truly p53 
independent should be further confirmed. An MdmX ChIP in cells lacking p53, for 
example, utilizing the HCT116 cells in which p53 was deleted, forming an 
isogenic cell line pair – with (HCT116+/+) and without (HCT116-/-) p53. In a 
preliminary experiment we confirmed that in HCT116+/+ cells targeting MdmX with 
four different siRNA sequences reduced Mdm2 expression following treatment 
with NCS (Fig. 4.2). In HCT116-/- cells that lack p53, there was no effect of down 
regulating MdmX on Mdm2 mRNA levels (Fig. 4.2A). Subjecting these cells to 
ChIP protocol would demonstrate whether MdmX still preferentially localizes to 
the Mdm2 promoter. 
 We showed that the inability to efficiently induce Mdm2 in response to 
NCS treatment in cells lacking MdmX impairs the formation of the p53:Mdm2 
feedback loop, leading to increased p53 half-life when compared to cells treated 
with control siRNA. Since this effect of MdmX on Mdm2 induction and p53 
stability is very time-dependent, it may have been over-looked in mouse models. 
In collaboration with the Lozano laboratory we plan to examine the effect of 
MdmX on Mdm2 induction in a mouse model. Mice with inducible MdmX knock-
out will be treated with gamma irradiation and tissues harvested shortly after will 
be examined for Mdm2 induction. In a preliminary experiment we tested whether 
MdmX impairs Mdm2 induction in MCF7 cells following treatment with gamma 
irradiation (5 Gy). MCF7 cells were transfected with control (siLuc) or MdmX 
siRNA for 48 hr, and then either mock treated (time 0) or irradiated with 5Gy  IR, 
and harvested every hour (Fig. 4.3). The responses to MdmX siRNA following  
IR were very similar to the responses following NCS treatment. Mdm2 mRNA 
peaks 4 hr post irradiation, and the levels are compromised in siMdmX-treated 
cells (Fig. 4.3A), while p21 mRNA levels are increased following siMdmX 
treatment (Fig. 4.3B). Mdm2 protein levels following  IR were reduced in cells 
treated with siMdm2, in agreement with the mRNA data (Fig. 4.3C). Thus, MdmX 
is required for Mdm2 induction following  IR, and we can proceed with the 
experiment using whole mouse irradiation to test the effect of MdmX knockout on 
Mdm2 induction. 
  
In chapter three we explored the effects of MdmX and Mdm2 down 
regulation on the expression of the PCNA gene. We showed that PCNA mRNA 
levels are reduced in response to treatment with siRNA targeting both MdmX and 
Mdm2 in the breast cancer MCF7 cells. Additionally, upon treatment with siRNA 
targeting MdmX or Mdm2 the levels of the p21 protein rose, and the cell cycle 
was arrested at the G1 phase. Since PCNA protein levels were not lowered, we 
concluded that the reduction in PCNA levels might be secondary to the increase 
in p21. p21 promotes inhibition of the transcription factor E2F (Dotto, 2000), 
which is a known activator of PCNA transcription (Li et al., 2003; Tommasi and 
Pfeifer, 1999). Whether MdmX or Mdm2 reduction exerts its effect on PCNA in a 
p21-dependent manner can be tested. MCF7 cells can be treated with siRNA 
targeting MdmX or Mdm2 alone or together with targeting p21. Additionally, 
PCNA levels can be examined in cells over-expressing p21 to confirm the 
hypothesis that p21 inhibits PCNA mRNA levels. Moreover, HCT116 cells in 
which p21 was knocked out (Waldman et al., 1995) can be used for testing p21 
dependence. In a preliminary experiment we showed that PCNA mRNA levels 
were reduced in HCT116+/+ cells in response to MdmX and Mdm2 siRNA (Fig. 
4.2C). 
Interestingly, in H1299 p53 null lung cancer cells down regulation of Mdm2 
but not MdmX leads to lower PCNA mRNA and protein levels. Although Mdm2 
was reported to promote proteasomal degradation of p21 (Jin et al., 2003), no 
visible increase in p21 mRNA or protein levels was observed. This suggests two 
possibilities. First, PCNA might be down regulated in response to the siRNA 
treatment, and the reduction in PCNA protein leads to cell cycle arrest. 
Alternatively, a p21-independent cell cycle arrest might be the primary response 
to the Mdm2 siRNA, leading, in turn, to E2F inhibition and thus to reduced PCNA 
levels. 
PCNA over-expression system can help testing whether limiting levels of 
PCNA protein in siMdm2-treated H1299 cells are the cause of cell cycle arrest. 
H1299 cells will be infected with retrovirus expressing PCNA, thus overriding the 
natural cell cycle regulation E2F1-mediated transcription of PCNA. If PCNA over-
expression bypasses the G1 arrest seen in cells after siMdm2 treatment, we 
would conclude PCNA reduction is the cause for the cell cycle arrest. We will 
then probe at the possible mechanisms by which Mdm2 may regulate PCNA 
expression.  
One way through which PCNA may be affected by siMdm2 is via Mdm2 
influencing E2F directly. Mdm2 was shown to interact with E2F and to stimulate 
the transcriptional activity of E2F1 and its binding partner DP1 (Martin et al., 
1995). Additionally, Mdm2 mediates E2F activation through interacting with pRb, 
the principal inhibitor of E2F1/DP1, in a p53-independent manner (Sdek et al., 
2004; Xiao et al., 1995), and targeting pRb for degradation (Sdek et al., 2005). 
The Mdm2-interacting region in E2F1 is highly similar to the Mdm2-binding 
sequence in p53 (Martin et al., 1995). Accordingly, Nutlin-3, a small molecule 
inhibitor of the Mdm2:p53 interaction (Vassilev et al., 2004) also inhibits 
Mdm2:E2F binding (Ambrosini et al., 2007). It is, therefore, possible to test the 
hypothesis that Mdm2 siRNA leads to reduced PCNA levels due to lack of 
stimulation of E2F1/DP1 by Mdm2 through comparing the response of H1299 
cells to siMdm2 versus Nutlin-3. 
In MCF7 cells an interpretation of such an experiment is more difficult, 
since Nutlin-3 activates p53, leading to induction of the cell cycle inhibitor p21 
(Fig. 4.4). MCF7 cells were transfected with control siRNA (siLuc) followed by no 
treatment, NCS, or Nutlin-3 treatment, or with siRNA targeting MdmX. PCNA 
mRNA levels were reduced by both Nutlin-3 as well as MdmX siRNA treatment, 
while unchanged in response to NCS treatment (Fig. 4.4A). Mdm2 and p21 
levels, on the other hand, were increased following both NCS and Nutlin-3 
treatment (Fig. 4.4B and 4.4C). Since p21 protein levels were greatly increased 
in cells treated with Nutlin-3 (Fig. 4.4D), we cannot conclude whether the 
reduction in PCNA mRNA levels resulted in from p21-induced cell cycle arrest or 
lack of Mdm2-mediated E2F activation.  
An additional method for probing Mdm2’s effects on the pRb-E2F pathway 
is through over-expressing ARF. ARF inhibits Mdm2 through inactivating its E3 
ligase activity as well as sequestering Mdm2 to the nucleolus (Honda and 
Yasuda, 1999; Midgley et al., 2000; Weber et al., 1999). H1299 stably expressing 
ARF have higher levels of pRb (Sdek et al., 2005), suggesting ARF inhibits 
Mdm2-mediated degradation of pRb. We hypothesize that over-expression of 
ARF would result in higher levels of pRb, leading to E2F inhibition and reduced 
PCNA levels. 
As we mentioned above, an alternative explanation for our results showing 
PCNA reduction in H1299 cells treated with Mdm2 siRNA may be due to p21-
independent cell cycle arrest. p27 is a CDK inhibitor that, like p21, promotes cell 
cycle arrest (Toyoshima and Hunter, 1994). p27 is a direct transcriptional target 
of FOXO transcription factors (Dijkers et al., 2000), which are regulated by the E3 
ligase activity of Mdm2 (Fu et al., 2009; Yang et al., 2008). It is, therefore, 
possible that down regulation of Mdm2 in H1299 cells leads to increased FOXO 
levels, activation of p27 and cell cycle arrest. siRNA targeting Mdm2 in H1299 
cells indeed leads to increased FOXO3A protein levels (Fu et al., 2009). Thus, 
H1299 cells will be transfected with control or Mdm2-targeting siRNA and cell 
lysates subjected to immunoblot analysis using antibodies against FOXO3A to 
confirm its activation, and p27 to examine whether its levels are increasing. If p27 
levels do rise in response to treatment with Mdm2 siRNA, a confirmation of their 
causal relationship to cell cycle arrest and PCNA reduction can be tested by 
examining whether down-regulation of p27 together with Mdm2 rescues the cell 
cycle arrest and reduction in PCNA levels caused by Mdm2 siRNA.  
An alternative mechanism through which Mdm2 down regulation in H1299 
cells may induce p21-independent cell cycle arrest is through the activation of the 
p53 family member p73. p73 is a p53 homolog (Jost et al., 1997; Kaghad et al., 
1997) that, like p53, can promote cell cycle arrest and apoptosis (Jost et al., 
1997; Melino et al., 2004). There are multiple isoforms of p73, with the isoforms 
expressed from the P1 promoter, which contain a trans activation domain 
(TAp73), possessing functional similarities to p53 (Irwin and Kaelin, 2001). Mdm2 
was shown to bind to p73 and inhibit its transcriptional activity without promoting 
its degradation (Balint et al., 1999; Dobbelstein et al., 1999; Gu et al., 2001; Zeng 
et al., 1999). In another study, however, over expressed Mdm2 stabilizes p73 
and enhances its transcriptional activity (Ongkeko et al., 1999). A later study 
demonstrated that Mdm2 mediates the NEDD8 modification of TAp73, promoting 
its nuclear export and inhibiting its activity (Watson et al., 2006). Nutlin-3 disrupts 
the interaction between Mdm2 and TAp73, leading to stabilization and activation 
of p73 (Lau et al., 2008). In addition to activating p21, p73 induces the 
expression of the CDK inhibitor p57 (Blint et al., 2002). p57 is not a target of p53, 
and its activation leads to cell cycle arrest at the G1 phase (Lee et al., 1995; 
Matsuoka et al., 1995). It is possible that Mdm2 down regulation by siRNA 
treatment in H1299 leads to activation of p73, which promotes p57 and leads to 
G1 arrest and inhibition of E2F, thus reducing PCNA levels. To test this 
hypothesis we will examine the levels of p73 and p57 in H1299 cells following 
treatment with control or Mdm2-targeting siRNA. An increase in p73 protein 
levels, and p57 mRNA and protein elevation will support our hypothesis. p73 
levels, however, may also increase in response to E2F activation. p73 is a 
transcriptional target of E2F, required for the activation of E2F1-induced 
apoptosis  (Irwin et al., 2000; Stiewe and Putzer, 2000; Urist et al., 2004). We 
will, therefore, quantitate the levels of p73 mRNA and examine whether E2F1 
interaction with the p73 promoter is increased in cells treated with siMdm2 
compared to control siRNA in order to test whether the effect of Mdm2 siRNA on 
p73 levels is direct or mediated through E2F activation.  
Since Nutlin-3 disrupts Mdm2 interaction with both E2F and p73 
(Ambrosini et al., 2007; Lau et al., 2008; Peirce and Findley, 2009), the 
experiment described above, in which H1299 cells will be treated with Nutlin-3 or 
siMdm2 and PCNA levels examined will have to be further evaluated. If PCNA 
levels are reduced in cells treated with Nutlin-3, we will examine the levels of 
E2F1 and its enrichment at the PCNA as well as the p73 promoters, and 
evaluate the levels of p73 protein and mRNA levels. 
Thus, based on the literature Mdm2 can impact PCNA levels through 
multiple mechanisms (Fig. 4.5). First, Mdm2 can target the CDK inhibitor p21 for 
degradation. This mechanism is unlikely taking place in H1299 cells since we did 
not see an increase in p21 protein levels upon Mdm2 ablation. Second, Mdm2 
may promote the activation of E2F directly or via the inhibition or pRb. Third 
mechanism is mediated via FOXO3A and its target p27, a target of Mdm2, and 
fourth mechanism is through Mdm2 inactivation of p73, an activator of p57. Of 
course, it is possible that none of the above hypotheses is correct, and an 
alternative mechanism is responsible for Mdm2 siRNA leading to p53-
independent down regulation of PCNA. Therefore, if the experiments described 
above do not support our hypotheses we will conduct a global analysis of 
changes in gene expression in H1299 cells in response to Mdm2 siRNA using 
microarray analysis.  
 To summarize, our observations of MdmX and Mdm2 regulating the 
expression of specific genes can be further explored to both study how specific 
these effects are using high throughput approaches such as microarray analyses 
to examine global changes in mRNA as well as enrichment of Mdm proteins at 
DNA sequences. Additionally, we can further explore the mechanisms through 
which MdmX or Mdm2 exert their effects on gene expression in the different cell 
lines. Finally, our observations can be extended to an in vivo system using 




 In this dissertation we explored the roles of MdmX and Mdm2 on the 
expression of p53 target genes. The observation that MdmX and Mdm2 have 
gene selective effects add to a growing body of knowledge suggesting roles of 
Mdm2 and MdmX beyond the inhibition of p53. With the p53 pathway being 
deregulated in majority of cancers (Olivier et al., 2010), specific Mdm2 and 
MdmX inhibitors are being developed (Brown et al., 2009; Toledo and Wahl, 
2007). Better understanding of Mdm2 and MdmX’s roles in the p53 pathway and 
beyond, will help predicting the therapeutic potentials and risks of their inhibition. 
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FIGURE LEGENDS 
Figure 4.1. MdmX recruitment to the Mdm2 promoter is not dependent on 
p53. MCF7 cells were transfected with 50 nM control siRNA (Luc) or siRNA 
targeting p53 (sip53). Cells were subjected to ChIP protocol using antibodies 
against p53 (A) or MdmX (B). Total mouse IgG was used as control (mouse 
IgG). ChIP-enriched DNA was quantitated by real time PCR with primers 
amplifying the Mdm2 P2 promoter. C. Immunoblot analysis of input material 
using antibodies against MdmX, p53 and actin. 
 
Figure 4.2. MdmX is required for Mdm2 induction in HCT116+/+ cells. 
HCT116+/+ and HCT116-/- cells were transfected for 48 hr with 50 nM control 
siRNA or four different siRNAs targeting MdmX, or siRNA targeting Mdm2. Cells 
were then either left untreated (NT) or treated with NCS (300 ng/mL) for 4 hr. 
Mdm2 (A), p21 (B) and PCNA (C) mRNA levels were quantitated by qRT-PCR 
analysis. D. Immunoblot analysis using antibodies against MdmX, Mdm2, p53, 
p21 and actin. 
 
Figure 4.3. MdmX is required for Mdm2 induction following 5 Gy  IR in 
MCF7. MCF7 cells were transfected with control (Luc) or MdmX siRNA (50 nM) 
for 48 hr followed by treatment with 5 Gy  irradiation and harvested at indicated 
times. 0 hr refers to non-irradiated cells. Mdm2 (A) and p21 (B) mRNA levels 
were determined using qRT-PCR. C. Immunoblot analysis using antibodies 
against MdmX, Mdm2, p53 and actin.  
 
Figure 4.4. PCNA mRNA levels are reduced following treatment with nutlin-
3 or MdmX siRNA. MCF7 cells were transfected with 50 nM of either control 
siRNA (siLuc) or MdmX siRNA (siMdmX). siLuc-treated cells were either left 
untreated (siLuc), treated with 300 ng/mL NCS (siLuc+NCS), or 10 M nutlin-3 
(siLuc+Nutlin), and siMdmX cells were left untreated (siMdmX). PCNA (A), p21 
(B) and Mdm2 (C) mRNA levels were determined using qRT-PCR. D. 
Immunoblot analysis using antibodies against MdmX, Mdm2, p53, p21 and actin.  
 
Figure 4.5. Possible mechanisms through which Mdm2 may regulate E2F 
activity. A model depicting alternative hypotheses through which Mdm2 may 
regulate PCNA via E2F.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 
 
 
 
 
 
Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 
